Page last updated: 2024-10-18

dalteparin and Thrombosis

dalteparin has been researched along with Thrombosis in 474 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.

Research Excerpts

ExcerptRelevanceReference
"Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110."10.17Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."9.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"6 μg/ml to unfractionated heparin (UFH), enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis under in vitro conditions."9.19In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. ( Buerke, M; Drouget, L; Hauroeder, B; Kaeberich, A; Krezel, C; Maedgefessel, L; Neuhart, E; Raaz, U; Schlitt, A; Vogt, A; Werdan, K, 2014)
"We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)."9.14Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009)
" The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture."9.12Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007)
"Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients."9.10Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003)
" Although warfarin is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid thrombosis syndrome, sticky platelet syndrome, and patients with malignancy and other medical conditions who have failed adequate warfarin doses."9.09Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report. ( Bick, RL; Rice, J, 1999)
"The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)."9.08Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997)
"Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy."9.08A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998)
"Bemiparin reduced intimal hyperplasia and prevented thrombosis angiogenesis, but dabigatran did not prevent intimal hyperplasia, and its anticoagulation effect was more than the antithrombotic effect."7.91Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy. ( Aydin Ozturk, P; Ozturk, U; Yilmaz, T, 2019)
"Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today."7.83Dalteparin-sodium induced drug fever in a neonate. ( Nydert, P; Obaya, S; Wackernagel, D, 2016)
"To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period."7.79Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013)
"In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin."7.77Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011)
"Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications."7.75Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009)
"Beginning in 2004, dalteparin doses based on activated clotting time (ACT) were administered for hepatic vessel thrombosis prophylaxis in living donor liver transplantation (LDLT)."7.75Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation. ( Ikegami, T; Masuda, Y; Mita, A; Miyagawa, S; Nakazawa, Y; Ohno, Y; Terada, M; Uchikawa, Y; Urata, K, 2009)
"Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy."7.74Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007)
"The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats."7.71Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002)
"We investigated the efficacy, safety and relation of dose to plasma anti-Xa activity of the low molecular weight heparin (LMWH) dalteparin in prophylaxis and therapy of arterial and venous thrombosis in pediatric patients."7.70The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. ( Auberger, K; Flemmer, A; Nohe, N; Praun, M; Rümler, R, 1999)
"To test the safety and feasibility of treating deep vein thrombosis (DVT) in an outpatient setting, using the low molecular weight heparin dalteparin, to calculate the potential and actual cost reductions achievable as a result of such a treatment regimen."7.69Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. ( Holmström, M; Lindmarker, P, 1996)
"However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis."6.82Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022)
"Catheter thrombosis has never been reported in any trial using bivalirudin."6.73Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008)
"Dalteparin or dextran was used during delivery."6.69Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998)
"One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb."6.68A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996)
"Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10,000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110."6.17Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. ( Colditz, GA; Menzin, J; Oster, G; Regan, MM; Richner, RE, 1995)
"Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT."5.72An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)
"Dalteparin can be used to treat thrombosis in newborn infants."5.62Dalteparin in Newborn Thrombosis, Time for a New Starting Dose. ( Bierings, M; Huisman, A; Steenman, F; Vijlbrief, DC, 2021)
"Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome."5.51Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019)
"ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries."5.43Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016)
"Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints."5.36Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. ( Buerke, M; Busshardt, M; Hauroeder, B; Maegdefessel, L; Plehn, A; Raaz, U; Schlitt, A; Werdan, K, 2010)
"Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH."5.36Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010)
"Dysfibrinogenemia is a disorder of fibrinogen structure and is associated with a functional abnormality."5.34Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis. ( Ganti, AK; Haire, WD; Vose, JM, 2007)
" Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied."5.33Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006)
" Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice."5.32Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."5.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"To assess the effect on thrombus growth, we determined the accretion of 125I-labeled fibrinogen onto autologous non-radioactive thrombi preformed in the jugular veins of rabbits."5.29Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. ( Biemond, BJ; Büller, HR; Levi, M; Nurmohamed, MT; ten Cate, JW, 1994)
"6 μg/ml to unfractionated heparin (UFH), enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis under in vitro conditions."5.19In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. ( Buerke, M; Drouget, L; Hauroeder, B; Kaeberich, A; Krezel, C; Maedgefessel, L; Neuhart, E; Raaz, U; Schlitt, A; Vogt, A; Werdan, K, 2014)
" Patients age > or =75 years treated with bivalirudin alone had similar ischemic outcomes, but significantly lower rates of bleeding compared with those treated with heparin and glycoprotein IIb/IIIa inhibitors overall and in the PCI subset."5.14Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. ( Alexander, KP; Bertrand, ME; Feit, F; Gersh, BJ; Hoekstra, J; Lopes, RD; Manoukian, SV; Ohman, EM; Pollack, CV; Stone, GW; White, HD, 2009)
"We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)."5.14Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009)
"In an analysis of the Melagatran Thrombosis Prophylaxis in Orthopedic Surgery (METHRO) III study, we evaluated whether concomitant administration of aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) with the direct thrombin inhibitor melagatran/ximelagatran or the low-molecular-weight heparin enoxaparin increased bleeding in patients undergoing major joint surgery."5.12Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. ( Agnelli, G; Andersson, M; Bylock, A; Cohen, AT; Dahl, OE; Eriksson, BI; Mouret, P; Ogren, M; Panfilov, S; Rosencher, N, 2006)
" The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture."5.12Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007)
"Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients."5.10Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003)
"In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure."5.09Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999)
" Although warfarin is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid thrombosis syndrome, sticky platelet syndrome, and patients with malignancy and other medical conditions who have failed adequate warfarin doses."5.09Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report. ( Bick, RL; Rice, J, 1999)
"5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, 100 IU/kg twice daily) in symptomatic proximal deep vein thrombosis."5.09Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. ( , 2000)
"The purpose of this study was to compare the efficacy and safety of treating mobile iliofemoral patients with deep venous thrombosis (DVT) with subcutaneous low-molecular-weight heparin (dalteparin sodium) either 200 IU/kg once-daily (group 1) or 100 IU/kg twice-daily (group 2)."5.08Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin. ( Kechavarz, B; Köhn, H; Lipp, C; Mostbeck, A; Partsch, H, 1996)
"The present trial investigated the efficacy and safety of dalteparin in the prevention of arterial thromboembolism after an acute anterior myocardial infarction (MI)."5.08Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. ( Abildgaard, U; Dale, J; Kontny, F; Pedersen, TR, 1997)
"Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy."5.08A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998)
"Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects."4.86P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010)
" Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin."4.85[The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009)
" Although low-molecular-weight heparin and direct oral anticoagulants, such as apixaban and rivaroxaban, have been evaluated for the prevention of catheter thrombosis, their efficacy remains uncertain."4.31Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. ( Fredenburgh, JC; Guan, Z; Hussain, RH; Jaffer, IH; Wang, R; Weitz, JI, 2023)
"ENSURE-AF (NCT02072434) assessed therapy with edoxaban vs enoxaparin-warfarin in patients with nonvalvular atrial fibrillation (AF) undergoing elective electrical cardioversion (ECV)."3.96Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. ( De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL, 2020)
"We report a 35-year old female with no cardiovascular risk factors who presented with thrombotic anterior wall myocardial infarction 6 months after using a third generation low dose combined oral contraceptive pills (Marvelon; ethinylestradiol 30 mcg and desogestrel 150 mcg)."3.96Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report. ( Adam, M; Al-Suwaidi, J; Aljundi, A; Khir, F; Mohsen, MK; Rahhal, A, 2020)
"Bemiparin reduced intimal hyperplasia and prevented thrombosis angiogenesis, but dabigatran did not prevent intimal hyperplasia, and its anticoagulation effect was more than the antithrombotic effect."3.91Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy. ( Aydin Ozturk, P; Ozturk, U; Yilmaz, T, 2019)
"Treatment with rivaroxaban was preferable over standard ACT with enoxaparin/warfarin with regards to the lysis of thrombus when duration of thrombosis did not exceed 10 days."3.83[Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis]. ( Agapov, AB; Kalinin, RE; Pshennikov, AS; Suchkov, IA, 2016)
"Drug fever caused by dalteparin-sodium (DS), a low-molecular-weight derivative of heparin, is neither listed in the official drug information and nor published as a case report until today."3.83Dalteparin-sodium induced drug fever in a neonate. ( Nydert, P; Obaya, S; Wackernagel, D, 2016)
" She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding."3.81Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? ( Baquero-Salamanca, M; Calderon-Ospina, C; Téllez-Arévalo, AM, 2015)
"Deep vein thrombosis was induced by exposure to ferric chloride or ligation of the infrarenal vena cava of C57BL/6 mice after pretreatment with enoxaparin, ticagrelor or vehicle and in P2Y(12-/-) mice."3.79Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition. ( Bode, C; Boeynaems, JM; Duerschmied, D; Guenther, F; Hein, L; Herr, N; Idzko, M; Mauler, M; Robaye, B; Roming, F; Von Zur Muhlen, C; Witsch, T, 2013)
"To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (TE) incidence in multiple myeloma (MM) patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one-year period."3.79Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital. ( Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC, 2013)
" Low-molecular-weight heparin (LMWH) has a longer plasma half-life and better bioavailability than standard heparin and can thus be administered as a single daily injection."3.78Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. ( Ben Maadi, A; Durand-Zaleski, I; Jazaerli, N; Mathieu, D; Petit-Phar, M; Radier, C; Rahmouni, A; Rosso, J; Rostoker, G; Vasile, N, 1995)
"A 35-year-old man developed priapism with the use of low-molecular-weight heparin and warfarin following repair of left brachial artery sustained after gunshot injury."3.78Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication! ( Goel, A; Kumar, A; Nagathan, DS; Pahwa, HS, 2012)
" Here, rivaroxaban, an oral, direct factor Xa (FXa) inhibitor, was compared with warfarin and enoxaparin in the prevention of right ventricular (RV) dysfunction and hypertrophy in the monocrotaline (MCT) model of pulmonary hypertension."3.77A role for coagulation factor Xa in experimental pulmonary arterial hypertension. ( Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G, 2011)
"In patients undergoing percutaneous coronary intervention, catheter thrombosis is more frequent with fondaparinux than heparin."3.77Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. ( Fredenburgh, JC; Liao, P; Roberts, R; Stafford, AR; Weitz, JI; Yau, JW, 2011)
"Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications."3.75Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009)
"Beginning in 2004, dalteparin doses based on activated clotting time (ACT) were administered for hepatic vessel thrombosis prophylaxis in living donor liver transplantation (LDLT)."3.75Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation. ( Ikegami, T; Masuda, Y; Mita, A; Miyagawa, S; Nakazawa, Y; Ohno, Y; Terada, M; Uchikawa, Y; Urata, K, 2009)
"Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy."3.74Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007)
" (2) The licence of dalteparin, a low-molecular-weight heparin (LMWH), has been extended in France to cover prophylaxis of deep venous thrombosis in patients confined to bed for heart failure, acute respiratory failure, acute infections or acute rheumatological conditions who have at least one other risk factor for venous thromboembolism."3.73Dalteparin: new indication. Prophylaxis in medical patients: no advance. ( , 2005)
" aspirin (4-30 mg/kg), heparin (100-500 U/kg), enoxaparin (4-30 mg/kg) and clopidogrel (10-20 mg/kg) were studied in a rat Folts-like preparation of carotid arterial thrombosis."3.73Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat. ( Daykin, HJ; Jones, C; Sturgeon, SA; Wright, CE, 2006)
" The rate of thrombosis rose to 10% (6/60) if no high-risk dose of dalteparin was applied subcutaneously."3.72Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing. ( Fung, S; Janssen, D; Kotowa, W; Lersch, C, 2004)
"This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy."3.71Enoxaparin treatment in women with mechanical heart valves during pregnancy. ( McCowan, LM; North, RA; Raudkivi, PJ; Rowan, JA, 2001)
"The antithrombotic effects of direct (ximelagatran and hirudin) and indirect (dalteparin) anticoagulants were compared using a deep venous thrombosis (DVT) treatment model in conscious rats."3.71Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. ( Carlsson, S; Elg, M; Mattsson, C, 2002)
" Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome."3.70Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000)
"We investigated the efficacy, safety and relation of dose to plasma anti-Xa activity of the low molecular weight heparin (LMWH) dalteparin in prophylaxis and therapy of arterial and venous thrombosis in pediatric patients."3.70The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. ( Auberger, K; Flemmer, A; Nohe, N; Praun, M; Rümler, R, 1999)
"LMWH (Fraxiparine), and NSAIDs (Aspirin, Feldene, Indocid and Profenid) injected together in doses, 1 mg/kg (Aspirin was used at 100 mg/kg), subcutaneously into rats 30 minutes before the thrombosis induction by LASER beams, increased the number of LASER beams required to induce platelet thrombus formation, decreased the number of emboli and reduced the duration of embolization, compared with control (p < or = 0."3.69Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. ( Aguejouf, O; Doutremepuich, C; Doutremepuich, F; Imbault, P; Oualane, FA, 1995)
"The effect of dalteparin, a low molecular weight heparin, on severely antithrombin III (ATIII)-decreased disseminated intravascular coagulation (DIC) model was compared with that of unfractionated heparin (heparin)."3.69Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. ( Fukuyama, J; Hamano, S; Ichikawa, K; Misawa, K; Miyata, H; Sakuragawa, N; Tazawa, S, 1995)
"To test the safety and feasibility of treating deep vein thrombosis (DVT) in an outpatient setting, using the low molecular weight heparin dalteparin, to calculate the potential and actual cost reductions achievable as a result of such a treatment regimen."3.69Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. ( Holmström, M; Lindmarker, P, 1996)
"Bleeding was predominantly intracranial (n=331 [69%]) or gastrointestinal (n=109 [23%])."3.30Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Cohen, AT; Connolly, SJ; Coppens, M; Crowther, M; Demchuk, A; Eikelboom, JW; Gibson, CM; Koch, B; Lopez-Sendon, J; Middeldorp, S; Milling, TJ; Schmidt, J; Shoamanesh, A; Verhamme, P; Xu, L, 2023)
"Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment."3.11Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. ( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022)
"Adult patients with cancer at the time they develop thrombosis."3.01Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. ( Eckman, MH; Gulati, S, 2023)
"Thromboprophylaxis dosing strategies using enoxaparin in elderly patients with renal disease are limited, while dose adjustments or monitoring of anti-Xa levels are recommended."2.90Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. ( Chamoun, N; Dimassi, H; Ghanem, G; Ghanem, H; Hachem, A; Hariri, E; Lteif, C; Mansour, H; Zalloum, R, 2019)
"However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis."2.82Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022)
"Rivaroxaban is a direct factor Xa inhibitor that prevents thrombus formation."2.82Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. ( Drabik, A; Eveslage, M; Gerss, J; Goerge, T; Kahle, B; Kreuter, A; Schneider, SW; Strölin, A; Weishaupt, C, 2016)
"Bleeding was predominantly gastrointestinal or intracranial."2.82Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016)
"Left ventricular (LV) thrombus is one of the most common complications in patients with anterior acute myocardial infarction (AMI) and LV dysfunction."2.80Comparison of the usefulness of enoxaparin versus warfarin for prevention of left ventricular mural thrombus after anterior wall acute myocardial infarction. ( Grines, CL; Grines, LL; Marcovitz, P; Messenger, J; Schreiber, T; White, DC, 2015)
" We present 52 patients treated with tinzaparin anticoagulation on HD, confirming that fixed dosing is safe and efficacious with sound pharmacodynamic reason in relation to anti-Xa profiling."2.78Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis. ( Ashman, N; Baig, ZF; Kirwan, CJ; MacCullum, PK; Platton, S, 2013)
"Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes."2.77Bioactivity of enoxaparin in critically ill patients with normal renal function. ( Gouya, G; Heinz, G; Kapiotis, S; Locker, G; Madl, C; Palkovits, S; Stella, A; Wolzt, M, 2012)
"Catheter thrombosis has never been reported in any trial using bivalirudin."2.73Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study. ( Buerke, M; Carter, JM; Hauroeder, B; Maegdefessel, L; Michel, T; Peetz, D; Reindl, I; Schlitt, A; Schubert, S; Werdan, K, 2008)
" In this pilot study 27 children with deep venous thromboses (DVT) were treated with the LMWH enoxaparin at a dosage of 1."2.72Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. ( Gunther, G; Merkel, N; Schobess, R, 2006)
"3% of patients no adverse event was reported."2.71Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. ( Eckert, M; Hafner, G; Hohmann, V; Klingel, R; Lotz, J; Schwarting, A, 2004)
"Once a diagnosis of left ventricular thrombus has been established, the classical attitude consists in the administration of unfractionated heparin relayed by oral anticoagulation therapy."2.71Treatment of left ventricular thrombi with a low molecular weight heparin. ( Bourmayan, C; Driss, AB; Grosdemouge, A; Meurin, P; Renaud, N; Tabet, JY; Weber, H, 2005)
"Three cases of intraprocedural thrombus occurred among patients who received enoxaparin."2.71Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial). ( Cohen, EA; Fort, S; Godin-Edgecombe, M; Madan, M; Naqvi, SZ; Paradiso-Hardy, FL; Phillips, AM; Radhakrishnan, S; Reis, M; Shanmugasegaram, S; Sparling, C, 2005)
"Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition."2.70Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001)
" As the PTT did not reach 40 seconds, the heparin sodium dosage was increased to 7,500 IU 3 times daily."2.69Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty. ( Eulert, J; Hendrich, C; König, A; Kramer, C; Rader, CP, 1998)
"Deep-vein thrombosis was detected in twenty-four (18 per cent) of the patients who used the foot pump compared with eighteen patients (13 per cent) who received enoxaparin (95 per cent confidence interval for the difference in proportions, -3."2.69Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. ( Donovan, J; Glew, D; Harrison, J; Mitchelmore, A; Peters, TJ; Warwick, D, 1998)
"Dalteparin or dextran was used during delivery."2.69Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998)
" Bleeding complications and other adverse events were registered throughout the study period."2.69Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. ( Andersen, G; Anderson, BS; Appelquist, E; Borris, LC; Christensen, F; Erin-Madsen, J; Hansen, BR; Hvidt, P; Hørlyck, E; Jensen, BV; Jensen, HP; Jensen, NK; Jørgensen, PS; Lassen, MR; Møller, JC; Nielsen, AB; Nielsen, JB; Paaske, B; Petersen, AO; Rotwitt, L; Siem, P; Skejø Bro, HP; Thomsen, PB; Tjalve, E; Tørholm, C, 1998)
" In these clinical studies, Enoxaparin, 30 mg twice daily, was shown to be as effective and safe as low dose unfractionated heparin to prevent deep venous thrombosis after hip arthroplasty."2.68Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. ( Colwell, CW; Spiro, TE, 1995)
" However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more predictable anticoagulant response of low-molecular-weight heparins make them attractive for possible home use."2.68A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. ( Anderson, D; Demers, C; Gent, M; Ginsberg, J; Hirsh, J; Kovacs, M; Leclerc, J; Levine, M; Turpie, AG; Weitz, J, 1996)
"The incidence of silent pulmonary embolism (PE) (new defect on V/Q scan) was 28% (8 out of 29) in patients with and 5% (2 out of 43) in patients without DVT (chi 2; p < 0."2.68Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. ( al-Kutoubi, A; Birch, R; Cunningham, DA; Fareed, J; Gill, K; Harris, N; Hoppensteadt, DA; Hunt, D; Johnson, J; Kalodiki, EP; Marx, C; Nicolaides, AN; Regan, F, 1996)
"One dalteparin-treated patient had a PE confirmed by V/Q scan; another had progressive thrombosis with swelling in the affected limb."2.68A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. ( Grankvist, S; Hallert, C; Jauro, I; Ketola, K; Kim, HC; Kiviniemi, H; Koskivirta, H; Luomanmäki, K; Sörskog, L; Vilkko, P, 1996)
"In order to define the optimal dosage of a low molecular weight enoxaparine (Lovenox) in the prevention of clotting in extracorporeal circulation during hemodialysis, a multicentre trial was conducted in 72 patients dialysed in seven hemodialysis units."2.67[Optimization of enoxaparin dose in the prevention of coagulation in the circuits of hemodialysis: results of a multicenter study]. ( Combe, S; de Groc, F; Debure, A; Dupuy, CA; Fievet, P; Küntziger, H; Reach, I; Teboulle, D; Thébaud, HE; Thoumazou, G, 1994)
"Two enoxaparin dosage regimens are used as comparators to evaluate new anticoagulants for thromboprophylaxis in patients undergoing major orthopaedic surgery, but so far no satisfactory direct comparison between them has been published."2.50Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs. ( Bertoletti, L; Chapelle, C; Cucherat, M; Darmon, JY; Laporte, S; Lega, JC; Mismetti, P; Zufferey, PJ, 2014)
"An association between cancer and thrombosis has been recognized since 1865."2.46Bemiparin in oncology. ( Lecumberri Villamediana, R; Monreal Bosch, M; Prandoni, P; Vignoli, A, 2010)
"To assess the prescribing practice of enoxaparin in comparison to dosing guidelines."2.46Current enoxaparin dosing guidelines have dubious credibility. ( Al-Sallami, H; Duffull, S; Ferguson, R; Jordan, S; Medlicott, N; Schollum, J, 2010)
" Future issues that need to be addressed include refinement of indications for administration and patient selection, comparison between existing agents, evaluation of newer agents, and optimization of dosing to maximize benefit and safety in the use of these powerful new classes of drugs."2.41Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. ( Vernon, SM, 2001)
" The pharmacokinetic and pharmacodynamic differences among LMWHs can be explained by comparing methods of preparation, molecular structures, half-lives, antithrombin- and non-antithrombin-mediated actions, effect on thrombus, and dosing interval."2.41Differentiation of the low-molecular-weight heparins. ( Racine, E, 2001)
" Studies have shown that weight-based dosing influences significantly both the time to reach a therapeutic intensity of anticoagulation and the incidence of thromboembolic recurrence."2.39Contemporary use of and future roles for heparin in antithrombotic therapy. ( Gibaldi, M; Wittkowsky, AK, 1995)
" This agent also showed sustained activity and better bioavailability characteristics than heparin."2.38Pharmacological profile of reviparin-sodium. ( Fareed, J; Hoppensteadt, D; Jeske, W, 1993)
"When guided by thrombus resolution on ultrasound, a four-week or shorter course of anticoagulation does not increase the need for surgical intervention or long-term complications."1.91Practice patterns in the management of pediatric iliofemoral arterial thrombosis. ( Acker, SN; Diaz-Miron, J; Hall, JK; Harrison, ML; Klein, G; Vaughn, AE; Yi, JA, 2023)
"When administered with the purpose of treating a thrombosis, the duration of treatment is six to twelve weeks."1.72Investigating the experience of parents who have given their infants enoxaparin at home. ( Gilmore, H; Jones, S; Monagle, P; Monagle, S; Newall, F, 2022)
"Thrombosis was observed in the PMMA group and ES-PMMA group but not in the sham group."1.72The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells. ( Ding, L; Fu, D; Hao, K; Qi, X; Sang, L; Shen, X; Sun, H, 2022)
"Apixaban is a direct factor Xa inhibitor that may be intended as an ideal alternative for the management of HIT."1.72An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia. ( Ansarinejad, N; Balouchzehi, S; Farasatinasab, M; Moghaddam, OM; Mohammadi, M; Nasiripour, S, 2022)
" There is no guideline regarding enoxaparin bridging in LVAD patients and a dosing strategy to ensure efficacy and safety is uncertain."1.72Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution. ( Alvarez, PA; Bernard, AM; Bream-Rouwenhorst, HR; Briasoulis, A; Czerniak, LC; Horner, KE, 2022)
"Thrombosis was associated with increasing age (median: 74."1.72Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study. ( Akinosoglou, K; Chatzistamati, A; Dimakopoulou, V; Efraimidis, G; Golemi, F; Kaiafa, G; Konstantinidou, A; Liontos, A; Markatis, E; Milionis, H; Mitsianis, A; Panagopoulos, P; Papanikolaou, IC; Papazoglou, D; Pavlaki, M; Pouliakis, A; Randou, E; Samaras, V; Savopoulos, C; Savvanis, S; Triantafyllidis, C; Vadala, C; Varela, K; Xarras, P, 2022)
"Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thrombosis (CAT) are scarce."1.72Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. ( Cajfinger, F; Crichi, B; Farge, D; Frere, C; Janus, N; Le Maignan, C; Marjanovic, Z; Rueda-Camino, JA; Spiess, N, 2022)
"Penile thrombosis has not been reported as a thrombotic complication of SARS-CoV-2 infection with hypercoagulability."1.62Priapism in a patient with coronavirus disease 2019 (COVID-19). ( Abbad, S; Chebbi, A; Lamamri, M; Legriel, S; Mamane, J; Munuzzolini, M; Sarfati, F, 2021)
" Enoxaparin dosing was nearly double the recommended starting doses for secondary thromboprophylaxis."1.62Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort. ( Dobbie, LJ; Eskell, L; Lamb, A; Ramage, IJ; Reynolds, BC, 2021)
"Enoxaparin is commonly used to treat pediatric thrombosis."1.62Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children. ( Abdel-Rasoul, M; Cloyd, C; Dunn, A; Kuhn, A; Steinbrenner, J; Tyrrell, L; Wysocki, EL, 2021)
"The Total Thrombus Analysis System (T-TAS), which is a microfluidic assay that simulates conditions in vivo, measures whole blood flow at defined shear rates under conditions designed to assess platelet function (PL-chip) or coagulation and fibrin clot formation (AR-chip)."1.62Analysis of blood clotting with the total thrombus analysis system in healthy dogs. ( Fukushima, R; Iwanaga, T; Maruyama, I; Miura, N; Nagasato, T, 2021)
"Dalteparin can be used to treat thrombosis in newborn infants."1.62Dalteparin in Newborn Thrombosis, Time for a New Starting Dose. ( Bierings, M; Huisman, A; Steenman, F; Vijlbrief, DC, 2021)
"History of prior deep vein thrombosis (HR 2."1.62Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study. ( Chatzis, D; Giannoukas, AD; Goumas, K; Karathanos, C; Latzios, P; Papakostas, I, 2021)
"Hospitalized cancer patients are at increased risk of thrombosis and prophylaxis with heparin is recommended."1.56Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. ( Ackerman, S; Haim, N; Keren-Politansky, A; Litvak, M; Maurice-Dror, C; Nadir, Y, 2020)
" An antithrombotic prophylaxis at low dosage was immediately started, then increased at prophylactic dosage."1.56How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. ( Campello, E; Pasca, S; Simioni, P; Spiezia, L; Vettor, R; Zanon, E, 2020)
"We present a late presentation of saddle pulmonary embolism and thrombus-in-transit straddle the patent foramen on patient who successfully recovered from severe acute respiratory syndrome coronavirus-2 (COVID-19) pneumonia."1.56Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset. ( Fontes, JD; Fujikura, K; Taub, CC, 2020)
" The purpose of the study was to evaluate the association between initial dosing strategy of thromboprophylaxis in critically ill COVID-19 patients and the risk of death, thromboembolism, and bleeding."1.56Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. ( Cronhjort, M; Dahlberg, M; Everhov, ÅH; Grip, J; Günther, M; Hollenberg, J; Järnbert-Pettersson, H; Jonmarker, S; Litorell, J; Schandl, A; Söderberg, M; Stackelberg, O, 2020)
" Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population."1.51Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis. ( Breese, EH; Jenkins, M; Luchtman-Jones, L; O'Brien, M; Sawyer, J; Young, J, 2019)
"Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome."1.51Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019)
"Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)."1.48Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018)
" We aimed to determine whether current enoxaparin dosing regimens effectively achieve anti-factor Xa concentrations within prophylactic goal ranges in this patient population."1.48Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD. ( Israel, EN; Mastropietro, CW; Thomas, CA, 2018)
"Dalteparin is a safe and effective anticoagulant when used for paediatric home HD."1.48Dalteparin anticoagulation in paediatric home haemodialysis. ( Hothi, DK; Lutkin, M; Stronach, L; Yadav, P, 2018)
" There is limited data comparing anticoagulation efficacy between subtypes of LMWH and dosing regimens in this context."1.48Mechanical Mitral Valve Thrombosis Secondary to Tinzaparin as an Anticoagulation Bridging Strategy. ( Harten, C; Kent, WDT; Vasanthan, V, 2018)
"Essentials The once-daily dosing of tinzaparin provides an advantage over other low molecular weight heparins."1.46Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis. ( Avery, P; Biss, TT; Murphy, P; Musgrave, KM; Webber, K, 2017)
" In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention."1.43[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016)
"ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries."1.43Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016)
"Neonatal myocardial infarction is a rare clinical entity that is associated with high mortality."1.42A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator. ( Dori, Y; Gillespie, MJ; Hallbergson, A, 2015)
"Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates."1.42Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates. ( Bhatt, MD; Chan, AK; Goldsmith, R; Paes, BA, 2015)
"Fondaparinux, was more vulnerable to the presence of cancer cells as compared to apixaban."1.42Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. ( Elalamy, I; Gerotziafas, GT; Larsen, A; Mbemba, E; Rousseau, A; Van Dreden, P, 2015)
"We describe a patient with a giant thrombus on the apical wall of the left ventricle that occurred due to HIT syndrome after anterior myocardial infarction."1.40Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI. ( Balaban Kocas, B; Coskun, U; Gultekin, N; Gurmen, T; Kucukoglu, S; Sinan, UY, 2014)
"Age, critical illness, and timing of AT3 had no effect on time to therapeutic anti-Xa levels."1.40Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis. ( Corder, A; Held, K; Oschman, A, 2014)
"Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss."1.39How I treat heterozygous hereditary antithrombin deficiency in pregnancy. ( Bramham, K; Hunt, BJ; Mitchell, M; Moore, GW; Retter, A; Robinson, SE, 2013)
" Enoxaparin was administered after caesarean section using the Royal College of Obstetricians and Gynaecologists weight-adjusted dosing guidelines."1.39Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. ( Casey, E; Hiscock, RJ; Newell, PA; Simmons, SW; Walker, SP, 2013)
"Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication."1.39Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013)
"As major bleeding has modifiable risk factors and is associated with in-hospital mortality, strategies to mitigate these factors should be evaluated in critically ill patients."1.39Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. ( Albert, M; Arnold, DM; Ashley, BJ; Cook, D; Crowther, M; Dodek, P; Finfer, S; Fowler, R; Heels-Ansdell, D; Karachi, T; Khwaja, K; Lauzier, F; Lopes, RD; McIntyre, L; Nates, JL; Ostermann, M; Rabbat, C; Skrobik, Y; Zarychanski, R; Zytaruk, N, 2013)
"Bioprosthetic valve thrombosis is an unexpected complication which has no guidelines for its management."1.37Successful thrombolysis of late, non-obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature. ( Lengyel, M; Pozsonyi, Z, 2011)
"No reductions were observed in the thrombus size or mean mitral gradient on transesophageal echocardiography (TEE) with 1 week of unfractioned heparin therapy."1.37Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis. ( Akcay, AB; Akcay, M; Davutoglu, V; Sen, N; Soydinc, HE; Yuce, M, 2011)
" Inadequate dosage has been pointed out as a potential problem because the use of subjectively estimated weight instead of real measured weight is common practice in the emergency department (ED)."1.37Error in body weight estimation leads to inadequate parenteral anticoagulation. ( de Oliveira, L; dos Reis Macedo, LG; Garcia, AA; Pazin-Filho, A; Pintão, MC, 2011)
"Primary end point was amount of valve thrombus at 30 days."1.37Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. ( Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM, 2011)
"Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease."1.37Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. ( Funatsu, T; Iwatsuki, Y; Kaku, S; Kawasaki, T; Moritani, Y; Sato, T; Shigenaga, T; Suzuki, M, 2011)
"Overall thrombus weight, anti-Xa activity and electron microscopic features such as deposits of platelets, erythrocytes and fibrin on the catheter surface were quantified as endpoints."1.36Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. ( Buerke, M; Busshardt, M; Hauroeder, B; Maegdefessel, L; Plehn, A; Raaz, U; Schlitt, A; Werdan, K, 2010)
"Heparin-induced thrombocytopenia is an antibody-mediated disorder exhibiting variable frequency in different clinical settings."1.36Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. ( Cook, RJ; Greinacher, A; Marder, VJ; Warkentin, TE, 2010)
"The prevalence of LAA thrombus among fully anticoagulated patients undergoing AF ablation is unknown."1.36Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation. ( Atwater, BD; Bahnson, TD; Crowley, AL; Daubert, JP; Hranitzky, PM; Voora, D; Wallace, TW, 2010)
"Coagulation parameters, overall thrombus weight and electron microscopic features (deposits of platelets and fibrin on the catheter surface) were quantified as endpoints."1.36The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. ( Buerke, M; Busshardt, M; Ebelt, H; Kaeberich, A; Maegdefessel, L; Plehn, A; Raaz, U; Russ, M; Schlitt, A; Schubert, S; Werdan, K, 2010)
"8 dosage adjustments was needed."1.36Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit? ( Berry, D; Chrysostomou, C; Gunawardena, S; Krallman, S; Morell, VO; Munoz, R; Orr, R; Sanchez de Toledo, J; Shiderly, D; Sonderman, S; Wang, L; Wearden, P, 2010)
"Fondaparinux was shown to be efficacious in the prevention of deep vein thrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and UFH."1.36Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies. ( Schiele, F, 2010)
"We present a rare case of a thrombus at the aortic arch found 1 month after cisplatin-based chemotherapy in a 50-year-old patient with a diagnosis of small cell lung cancer; there were no symptoms related to the thrombus."1.36Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer. ( Baek, SK; Chin, SO; Choi, CW; Han, JJ; Hwang, YH; Lee, JJ; Maeng, CH, 2010)
"This is the first case of renal infarction that developed in the early hours of primary PCI, despite effective anticoagulant and antiplatelet treatment."1.36Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids. ( Calık, AN; Demirci, D; Güvenç, TS; Ilhan, E, 2010)
"Dalteparin was used as a reference compound."1.36Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010)
"Body weight is an important risk factor for thromboses and is used in algorithms to determine dosages in prophylaxis."1.35A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery. ( Grohs, JG; Lunzer, A; Vavken, P, 2009)
"Preprocedural TEE revealed LA thrombus in 12 of 732 cases (1."1.35Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation. ( Abraham, TP; Berger, RD; Calkins, H; Cheng, A; Chilukuri, K; Dalal, D; Dong, J; Henrikson, CA; Marine, JE; Nazarian, S; Scherr, D; Spragg, D, 2009)
"Spontaneous aortic thrombosis is rare."1.35Aortic thrombosis in infancy. ( Mehta, AV; Teixeira, OH, 2009)
"Patients with brain tumors including intracranial meningiomas are at increased risk for developing deep vein thrombosis (DVTs) and suffering thromboembolic events (VTEs)."1.35Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas. ( Berger, MS; Cage, TA; Chakalian, L; Frankfurt, A; Lamborn, KR; McDermott, MW; Ware, ML, 2009)
" Therefore, we believe that intravenous enoxaparin is a safe alternative to unfractionated heparin in both settings."1.35Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention. ( Cheong, BY; Díez, JG; Ferguson, JJ; Medina, HM; O'Meallie, L, 2009)
"It led to a complete resolution of the thrombus in 4 weeks without the need for a high-risk operation in this patient."1.35Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder. ( Chojnowska, L; Hoffman, P; Klopotowski, M; Konka, M; Maczynska, R; Malek, LA; Ruzyllo, W; Skwarek, M, 2008)
"Furthermore, thrombus weight and the cell/fibrinogen counts were significantly increased in fonda and fonda+eptifibatide compared with other treatment groups."1.35In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. ( Buerke, M; Carter, JM; Ebelt, H; Hauroeder, B; Kropff, SS; Maegdefessel, L; Peetz, D; Reindl, I; Rupprecht, HJ; Russ, M; Schlitt, A; Schmidt, H; Schubert, S; Werdan, K, 2008)
"Since low molecular weight heparin has greater bioavailability and sustained serum levels in vivo than unfractionated heparin, it has been used to supplant unfractionated heparin to achieve therapeutic anticoagulation in humans."1.35Enoxaparin does not ameliorate limb ischemia-reperfusion injury. ( Abbruzzese, TA; Albadawi, H; Kang, J; Lamuraglia, GM; Patel, VI; Watkins, MT; Yoo, JH, 2008)
"The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered."1.35The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009)
"Dysfibrinogenemia is a disorder of fibrinogen structure and is associated with a functional abnormality."1.34Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis. ( Ganti, AK; Haire, WD; Vose, JM, 2007)
"The results between cancer-activated and tissue factor-activated blood were similar."1.34Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. ( Cloonan, ME; DiNapoli, M; Mousa, SA, 2007)
"Of these, macroscopic thrombus was observed on PCI equipment in 6 patients (5%) necessitating withdrawal of all catheters and wires."1.34Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin. ( Barbeau, GR; Cloutier, S; Dana, A; Nguyen, CM, 2007)
" An initial dosage of 1."1.34Enoxaparin use in the neonatal intensive care unit: experience over 8 years. ( Chan, AK; Knoppert, DC; Lee, DS; Malowany, JI; Pepelassis, D, 2007)
"This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether the ACT or aPTT can be used to monitor intravenous (IV) low molecular weight heparin (LMWH)."1.33The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration. ( Cavusoglu, E; Lakhani, M; Marmur, JD, 2005)
" Pharmacokinetic studies determined optimal dosing for clinically relevant anticoagulant levels in mice."1.33Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. ( Choi, SH; Stevenson, JL; Varki, A, 2005)
" Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied."1.33Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006)
"The efficacy of LMWH in resolving thrombus in children is, however, unknown and may differ from what has been observed in adults due to known differences in the hemostatic system."1.32Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. ( Chan, A; Daneman, A; Dix, D; Marzinotto, V; Massicotte, P; Revel-Vilk, S; Sharathkumar, A, 2004)
"To evaluate the ability of published dosage guidelines for enoxaparin to achieve therapeutic anticoagulation and to determine whether the routine monitoring of anti-Xa levels is still necessary at a tertiary care pediatric institution."1.32An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. ( Dix, DB; Hamilton, DP; Ho, SH; Wadsworth, LD; Wu, JK, 2004)
" Low-molecular-weight heparins prevent venous thrombosis as effectively as heparin and have better bioavailability and a longer plasma half-life, which explains the increased use of low-molecular-weight heparins as substitutes for heparin in clinical practice."1.32Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. ( Arnljots, B; Dahlbäck, B; Malm, K, 2003)
"Immediately following, the thrombus was removed, dried and weighed 24 h later."1.32Orally administered heparins prevent arterial thrombosis in a rat model. ( Hiebert, LM; Pinel, C; Wice, SM, 2004)
"In the venous thrombosis model at the maximally effective dose, C921-78 had minimal extension of ex vivo clotting parameters, while enoxaparin and unfractionated heparin demonstrated a two to sevenfold increase in activated partial thromboplastin times, and PPACK had a threefold extension of thrombin clotting times."1.31Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. ( Hollenbach, SJ; Ku, P; Lin, PH; Malinowski, J; Marlowe, CK; Scarborough, RM; Sinha, U; Wong, PW; Zhu, BY, 2000)
"Enoxaparin 1 mg/kg intravenously every eight hours was used safely in this preterm infant with suspected thrombosis, suggesting that more than one dosing regimen may be appropriate in this population."1.31Use of enoxaparin in a preterm infant. ( Dunaway, KK; Gal, P; Ransom, JL, 2000)
"The time to formation of an occlusive thrombus in the femoral arteries averaged 69+/-5 min in the control group compared to 127+/-19, 192+/-33 and 219+/-15 min in the low-, mid- and high-dose CI-1031 groups."1.31The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. ( Hicks, GW; Janiczek-Dolphin, N; Juneau, PL; Leadley, R; McClanahan, TB; Mertz, TE; Morrison, AL; Morser, J; Peng, YW; Sullivan, ME, 2001)
"The aim of this trial, undertaken with the participation of 13 centres, was to establish the minimal effective dosage of nadroparin (Fraxiparin) for the prevention of left ventricular mural thrombosis in acute anterior myocardial infarction which was not treated by thrombolysis."1.30[Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study]. ( Charbonnier, B, 1997)
"These cases provide evidence of type IV hypersensitivity and the possibility of crossed-allergenicity among unfractionated heparin and low-molecular-weight heparins."1.30Delayed-type hypersensitivity to subcutaneous enoxaparin. ( Armentia, A; de la Fuente, R; Fernández, A; Martínez, C; Méndez, J; Sánchez, P; Sanchís, ME; Stolle, R; Vega, JM, 1998)
"To assess the effect on thrombus growth, we determined the accretion of 125I-labeled fibrinogen onto autologous non-radioactive thrombi preformed in the jugular veins of rabbits."1.29Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. ( Biemond, BJ; Büller, HR; Levi, M; Nurmohamed, MT; ten Cate, JW, 1994)
"This study compares the pharmacokinetic and the antithrombotic properties of two pentasaccharides with high affinity to antithrombin III with those of a conventional low molecular weight heparin, CY216, in the rabbit."1.29Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. ( Boneu, B; Caranobe, C; Carrie, D; Houin, G; Lormeau, JC; Meuleman, D; Petitou, M; Saivin, S; Van Boeckel, C, 1994)
"Aprosulate sodium was the first representative of a new class of synthetic polyanions showing antithrombotic efficacy in different animal models."1.29Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties. ( Elling, H; Klauser, RJ; Meinetsberger, E; Raake, W; Zeiller, P, 1994)
"The relative number of grafts with thrombus free surface was increased in the unrestricted blood flow situation."1.29Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep. ( Bergqvist, D; Lindblad, B; Lundell, A; Matthiasson, SE, 1995)
"We found evidence of only parietal thrombus formation 3 times (10%) in the arteries and 4 times (13."1.29[Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration]. ( Slunsky, R, 1995)
"Platelet dependent thrombus deposition was quantified by dedicated image analysis after transillumination of the femoral vein to which a standardised vascular trauma was applied."1.29Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo. ( Deckmyn, H; Lambeir, AM; Matthyssens, G; Nyström, A; Stassen, JM; Vermylen, J; Vreys, I, 1995)
"Histology at day 1 showed that thrombus in the occluded vessels adhered to the exposed adventitia in the crushed area or the adventitia was covered by fibrin, red blood cells, and platelet mesh in the patent vessels."1.29Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. ( Chen, LE; Korompilias, AV; Seaber, AV; Urbaniak, JR, 1995)
" Fourteen children had a deep vein thrombosis or pulmonary embolism, nine had thrombotic complications in the central nervous system, and two had complex congenital heart disease, for which they received prophylaxis at a lower dosage (0."1.29Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. ( Adams, M; Andrew, M; Brooker, LA; Marzinotto, V; Massicotte, P, 1996)
"Dextran reduced the thrombus weights (p = 0."1.29Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. ( Bergqvist, D; Holst, J; Lindblad, B; Matthiasson, SE; Mätzsch, T, 1994)
" Thirty-three pigs received bolus injections of 300 IU/kg with or without additional dosage during CPB and with or without subsequent protamine sulphate."1.29Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. ( Bagge, L; Holmer, E; Malm, T; Nyström, SO; Tydén, H; Wahlberg, T, 1994)
" The standard dosage of heparin (1,500 IU, n = 6) was compared with a lower dosage (1,000 IU, n = 3) and several dosages of Fragmin (IU anti-FXa): 750 (n = 1), 1,500 (n = 3), 2,100 (n = 4) and 2,500 (n = 3)."1.29Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting. ( Bagge, L; Holmer, E; Nyström, SO; Tydén, H; Wahlberg, T, 1994)
"During all low-dose treatments, marked thrombus formation occurred in the extracorporeal circuit, and in 2, the circuit clotted within the study period."1.29Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. ( Davison, AM; Douglas, JT; Jeffrey, RF; Khan, AA; Will, EJ, 1993)

Research

Studies (474)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's84 (17.72)18.2507
2000's160 (33.76)29.6817
2010's154 (32.49)24.3611
2020's76 (16.03)2.80

Authors

AuthorsStudies
Eck, RJ1
van de Leur, JJCM1
Wiersema, R1
Cox, EGM1
Bult, W1
Spanjersberg, AJ1
van der Horst, ICC1
Lukens, MV1
Gans, ROB1
Meijer, K1
Keus, F1
Piwowarczyk, P1
Borys, M1
Kutnik, P1
Szczukocka, M1
Sysiak-Sławecka, J1
Szułdrzyński, K1
Ligowski, M1
Drobiński, D1
Czarnik, T1
Czuczwar, M1
Atamanova, EA1
Andryukhin, MI1
Vasilenko, IA1
Makarov, OV1
Simeone, R1
Giacomello, R1
Bruno, G1
Parco, S1
Maximova, N1
Martinelli, M1
Zito, G1
Luppi, S1
Cervi, G1
Ricci, G1
Bulatovic, A1
Schlieper, G1
Stankovic-Popovic, V1
Vujic, D1
Floege, J1
Dimkovic, N1
Enajat, M1
Aziz Mohammadi, M1
Debeij, J1
van der Hulst, RR1
Mureau, MA1
Duzhyĭ, ID1
Kravets', OV1
Hres'ko, IIa1
Iurchenko, AV1
Sandner, SE1
Zimpfer, D1
Zrunek, P1
Steinlechner, B1
Rajek, A1
Schima, H1
Wolner, E1
Wieselthaler, GM1
Somonova, OV1
Madzhuga, AV1
Elizarova, AL1
Zubrikhina, GN1
Vlasin, M1
Dvorak, M1
Dvorakova, M1
Rauser, P1
Lexmaulova, L1
Gregor, Z1
Pozsonyi, Z1
Lengyel, M1
Leger, P1
Cambus, JP1
Herault, JP1
Herbert, JM1
Boneu, B2
Betrosian, AP1
Theodossiades, G1
Lambroulis, G1
Kostantonis, D1
Balla, M1
Papanikolaou, M1
Georgiades, G1
Mismetti, P2
Mille, D1
Laporte, S2
Charlet, V1
Buchmüller-Cordier, A1
Jacquin, JP1
Fournel, P1
Dutrey-Dupagne, C1
Decousus, H1
Obergfell, A1
Langenfeld, H1
Hopp, H1
Steigerwald, U1
Grossmann, R1
Benvenuti, L1
Gagliardi, R1
Peternel, L1
Drevensek, G1
Cerne, M1
Stalc, A1
Stegnar, M1
Budihna, MV1
Lee, JH2
Park, NH1
Keum, DY1
Choi, SY1
Kwon, KY1
Cho, CH1
Doutremepuich, F1
Aguejouf, O1
Imbault, P1
Oualane, FA1
Doutremepuich, C1
Thomas, L1
Tyburn, B1
Bucher, B1
Pecout, F1
Ketterle, J1
Rieux, D1
Smadja, D1
Garnier, D1
Plumelle, Y1
Biemond, BJ1
Levi, M2
Nurmohamed, MT1
Büller, HR1
ten Cate, JW1
Carrie, D1
Caranobe, C1
Saivin, S1
Houin, G1
Petitou, M1
Lormeau, JC1
Van Boeckel, C1
Meuleman, D1
Krupiński, K1
Bielawiec, M2
Breddin, HK3
Raake, W1
Klauser, RJ1
Elling, H1
Zeiller, P1
Meinetsberger, E1
Tschammler, A1
Markert, T1
Wittenberg, G1
Krahe, T1
Bachmann, F1
Koopman, MM1
Prandoni, P3
Piovella, F1
Ockelford, PA1
Brandjes, DP1
van der Meer, J1
Gallus, AS1
Simonneau, G1
Chesterman, CH1
Prins, MH1
Elikowski, W1
Psuja, P1
Lewandowski, K1
Przybył, M1
Wendland, M1
Wróblewski, D1
Jazienicki, B1
Przybył, L1
Zawilska, K1
Ruiz-Valverde, MP1
Barberà, JR1
Segarra, A1
Capdevila, JA1
Evangelista, A1
Piera, L1
Goldsmith, DJ1
Charbonnier, B1
Martineau, P1
Tawil, N1
Giedrojć, J1
Klimiuk, M1
Radziwon, P1
Kłoczko, J1
Kobza, II1
Lagro, SW1
Verdonck, LF1
Borel Rinkes, IH1
Dekker, AW1
Vernon, SM1
Hofmann, S1
Knoefler, R1
Lorenz, N1
Siegert, G1
Wendisch, J1
Mueller, D1
Taut-Sack, H1
Dinger, J1
Kabus, M1
Vrij, AA1
Jansen, JM1
Schoon, EJ1
de Bruïne, A1
Hemker, HC2
Stockbrügger, RW1
Kargin, VD1
Rzhevskaia, VN1
Saltykova, NB1
Kapustin, SI1
Papaian, LP1
Kaplunov, OA1
Kaplunov, KO1
Trunfio, M1
Salvador, E1
Cabodi, D1
Marinaro, L1
Alcantarini, C1
Gaviraghi, A1
Trentalange, A1
Lipani, F1
Sciascia, S1
Roccatello, D1
Bonora, S1
Di Perri, G1
Calcagno, A1
Florian-Kujawski, M1
Hoppensteadt, D3
Maddineni, J1
Ziegler, H1
Fareed, J5
Sagüillo, K1
Pérez-Flecha, F1
Almeida, F1
Picón, M1
Acero, J1
Aydin Ozturk, P1
Yilmaz, T1
Ozturk, U1
Vavken, P1
Lunzer, A1
Grohs, JG1
San Juan Alvarez, M1
Márquez Garrido, G1
Rodríguez Bertos, C1
González Pérez, L1
Monreal Bosch, M1
Vignoli, A1
Lecumberri Villamediana, R1
Rocha, E1
Gómez-Outes, A1
Martínez González, J1
Kakkar, VV3
Kalçık, M1
Güner, A1
Kalkan, S1
Özkan, M2
Sarangi, SN1
Gaballah, M1
Nolfi-Donegan, D1
Battaglia, M1
Amin, S1
Amodio, J1
Acharya, SS1
Sibai, H1
Atenafu, EG1
Seki, JT1
Belmouaz, M1
Goussard, G1
Joly, F1
Grand, F1
Sibille, A1
Ecotiere, L1
Desport, E1
Bauwens, M1
Thierry, A1
Bridoux, F1
Farkouh, ME1
Stone, GW4
Lala, A1
Bagiella, E1
Moreno, PR1
Nadkarni, GN1
Ben-Yehuda, O1
Granada, JF1
Dressler, O1
Tinuoye, EO1
Granada, C1
Bustamante, J1
Peyra, C1
Godoy, LC1
Palacios, IF1
Fuster, V2
Cloyd, C2
Wysocki, EL2
Johnson, H1
Miller, JC1
Davis, J1
Galantowicz, M1
Yates, AR1
Gilmore, H1
Jones, S1
Monagle, P3
Monagle, S1
Newall, F1
Saithong, S1
Saisorn, W1
Tovichayathamrong, P1
Filbertine, G1
Torvorapanit, P1
Wright, HL1
Edwards, SW1
Leelahavanichkul, A1
Hirankarn, N1
Chiewchengchol, D1
Sang, L1
Hao, K1
Ding, L1
Shen, X1
Sun, H1
Fu, D1
Qi, X1
Farasatinasab, M1
Balouchzehi, S1
Moghaddam, OM1
Ansarinejad, N1
Mohammadi, M1
Nasiripour, S1
Centers, GI1
Hege, KM1
Nitu, ME1
Cristea, IA1
Yabrodi, M1
Schade Willis, TM1
Bhai, H1
Faustino, EVS2
Barco, S2
Voci, D1
Held, U2
Sebastian, T2
Bingisser, R2
Colucci, G2
Duerschmied, D2
Frenk, A2
Gerber, B2
Götschi, A1
Konstantinides, SV1
Mach, F2
Robert-Ebadi, H1
Rosemann, T2
Simon, NR1
Spechbach, H1
Spirk, D1
Stortecky, S2
Vaisnora, L1
Righini, M2
Kucher, N2
Fioretti, AM2
Leopizzi, T2
Puzzovivo, A2
Giotta, F2
Lorusso, V2
Luzzi, G2
Oliva, S2
Parker, RI1
Saadoun, R1
Bengur, FB1
Moroni, EA1
Surucu, Y1
Veit, JA1
Khan, NI1
Daniels, K1
Rothenberger, SD1
Kubik, M1
Solari, MG1
Sridharan, S1
Albisinni, R2
Vitrone, M2
Ursi, MP2
Spiezia, S2
Salemme, A2
Florio, LL2
Boccia, F2
Iossa, D2
Zampino, R2
Atripaldi, L2
Squillante, F2
Maturo, N2
Fraganza, F2
Severino, S2
Punzi, R2
Fiorentino, G2
Gulati, S1
Eckman, MH1
Guan, Z1
Wang, R1
Hussain, RH1
Fredenburgh, JC2
Jaffer, IH1
Weitz, JI3
Milling, TJ2
Middeldorp, S2
Xu, L1
Koch, B1
Demchuk, A1
Eikelboom, JW3
Verhamme, P3
Cohen, AT4
Beyer-Westendorf, J3
Gibson, CM2
Lopez-Sendon, J2
Crowther, M3
Shoamanesh, A1
Coppens, M1
Schmidt, J2
Albaladejo, P2
Connolly, SJ2
Durila, M1
Berousek, J1
Vlasakova, V1
Vymazal, T1
Hachenberger, M1
Yeniguen, M1
Suenner, L1
Hinchliffe, D1
Mueller, C2
Wietelmann, A1
Gerriets, T1
Tschernatsch, M1
Juenemann, M1
Gerner, ST1
Doeppner, TR1
Huttner, HB1
Braun, T1
Vaughn, AE1
Hall, JK1
Harrison, ML1
Klein, G1
Diaz-Miron, J1
Yi, JA1
Acker, SN1
Karahan, F1
Ünal, S1
Tezol, Ö1
Sürmeli Döven, S1
Durak, F1
Alakaya, M1
Mısırlıoğlu, M1
Yeşil, E1
Kıllı, İ1
Kurt, H1
Altunköprü, G1
Alexander, M2
Harris, S1
Underhill, C1
Torres, J1
Sharma, S2
Lee, N1
Wong, H1
Eek, R1
Michael, M1
Tie, J1
Rogers, J1
Heriot, AG1
Ball, D1
MacManus, M1
Wolfe, R1
Solomon, BJ1
Burbury, K1
Dziri, C1
Ben Hmida, W1
Dougaz, W1
Khalfallah, M1
Samaali, I1
Jerraya, H1
Bouasker, I1
Nouira, R1
Chen, S1
Schmidt, B1
Tohoku, S1
Trolese, L1
Bordignon, S1
Chun, KRJ1
Raskob, GE1
Spyropoulos, AC1
Spiro, TE2
De Sanctis, Y1
Xu, J1
Lu, W1
Suh, E1
Argenti, D1
Yang, H1
Albanese, J1
Lipardi, C1
Barnathan, ES1
Sudhakar, D1
Kamran, H1
Chen, N1
Mims, M1
Hamzeh, I1
Kozieł, M1
Merino, JL1
De Caterina, R2
Huber, K1
Jin, J1
Melino, M1
Goette, A1
Lip, GYH4
Rahhal, A1
Khir, F1
Adam, M1
Aljundi, A1
Mohsen, MK1
Al-Suwaidi, J1
Maurice-Dror, C1
Litvak, M1
Keren-Politansky, A1
Ackerman, S1
Haim, N1
Nadir, Y2
Cattaneo, M1
Morici, N1
Singh, N1
Singh Lubana, S1
Tsai, HM1
Zanon, E1
Pasca, S1
Campello, E1
Spiezia, L1
Vettor, R1
Simioni, P1
Lamamri, M1
Chebbi, A1
Mamane, J1
Abbad, S1
Munuzzolini, M1
Sarfati, F1
Legriel, S1
Fujikura, K1
Fontes, JD1
Taub, CC1
Ferguson, K1
Quail, N1
Kewin, P1
Blyth, KG1
Mattioli, M1
Benfaremo, D1
Mancini, M1
Mucci, L1
Mainquà, P1
Polenta, A1
Baldini, PM1
Fulgenzi, F1
Dennetta, D1
Bedetta, S1
Gasperoni, L1
Caraffa, A1
Frausini, G1
Chen, PF1
Yi, JL1
Pei, JY1
Tang, L1
Fang, ZF1
Zhou, SH1
Hu, XQ1
Mazzolai, L1
Spescha, R1
Windecker, S1
Lazar, M1
Tomey, MI1
Ghia, S1
Katz, D1
Derr, K1
Narula, J1
Bhatt, HV1
Carmo Filho, A1
Cunha, BDS1
Lemos, ACB1
do Espírito Santo, DA1
Salvetti, MC1
Gilio, RN1
Agra, LB1
Pazin-Filho, A2
Miranda, CH1
Bikdeli, B3
Talasaz, AH3
Rashidi, F3
Sharif-Kashani, B3
Farrokhpour, M3
Bakhshandeh, H3
Sezavar, H1
Dabbagh, A3
Beigmohammadi, MT3
Payandemehr, P3
Yadollahzadeh, M3
Riahi, T3
Khalili, H3
Jamalkhani, S3
Rezaeifar, P3
Abedini, A3
Lookzadeh, S3
Shahmirzaei, S3
Tahamtan, O3
Matin, S3
Amin, A3
Parhizgar, SE3
Jimenez, D3
Gupta, A3
Madhavan, MV3
Parikh, SA3
Monreal, M4
Hadavand, N3
Hajighasemi, A3
Maleki, M3
Sadeghian, S3
Mohebbi, B3
Piazza, G3
Kirtane, AJ3
Krumholz, HM3
Goldhaber, SZ3
Sadeghipour, P5
Cattelan, AM1
Carrozzi, L1
Leone, L1
Filippi, L1
De Gaudenzi, E1
Villalta, S1
Pesavento, R1
Belcaro, G1
Corsi, M1
Agus, GB1
Cesarone, MR1
Cornelli, U1
Cotellese, R1
Feragalli, B1
Hu, S1
Dobbie, LJ1
Lamb, A1
Eskell, L1
Ramage, IJ1
Reynolds, BC1
Arachchillage, DRJ1
Shi, C1
Saliu, D1
Kozman, P1
Mi, E1
Buti, N1
Kashef, E1
Copley, SJ1
Gomez, C1
Leonard, R1
Aziz, R1
Shlebak, AA1
Laffan, M1
Kuhn, A1
Steinbrenner, J1
Tyrrell, L1
Abdel-Rasoul, M1
Dunn, A1
Raffini, LJ1
Hanson, SJ1
Cholette, JM1
Pinto, MG1
Li, S1
Kandil, SB1
Nellis, ME1
Shabanova, V1
Silva, CT1
Tala, JA1
McPartland, T1
Spinella, PC1
Lv, Y1
Bai, W1
Li, K1
Wang, Z1
Guo, W1
Luo, B1
Wang, J1
Wang, Q1
Wang, E1
Xia, D1
Li, X1
Yuan, J1
Han, N1
Niu, J1
Yin, Z1
Fan, D1
Han, G1
Bernard, AM1
Alvarez, PA1
Bream-Rouwenhorst, HR1
Horner, KE1
Briasoulis, A1
Czerniak, LC1
Kirkup, C1
Pawlowski, C1
Puranik, A1
Conrad, I1
O'Horo, JC1
Gomaa, D1
Banner-Goodspeed, VM1
Mosier, JM1
Zabolotskikh, IB1
Daugherty, SK1
Bernstein, MA1
Zaren, HA1
Bansal, V1
Pickering, B1
Badley, AD1
Kashyap, R1
Venkatakrishnan, AJ1
Soundararajan, V1
Sezavar, SH2
Moghadam, KG2
Rahmani, H2
Zoghi, E2
Mohammadi, K2
Abri, H2
Tabrizi, S2
Mousavian, SM2
Rafiee, F2
Baghizadeh, E2
Aliannejad, R2
Eslami, V2
Kashefizadeh, A2
Kakavand, H2
Hosseini, SH2
Shafaghi, S2
Ghazi, SF2
Najafi, A2
Sethi, SS2
Van Tassell, BW2
Dobesh, PP2
Lopes, RD3
de Barros E Silva, PGM1
Furtado, RHM1
Macedo, AVS1
Ramacciotti, E2
Damini, LP1
Bronhara, B1
Cavalcanti, AB1
Rosa, RG1
Azevedo, LCP1
Veiga, VC1
Machado, FR1
Ritt, LE1
Martins, PA1
Alexander, JH1
Avezum, A1
Berwanger, O1
Perepu, US1
Chambers, I1
Wahab, A1
Ten Eyck, P1
Wu, C1
Dayal, S1
Sutamtewagul, G1
Bailey, SR1
Rosenstein, LJ1
Lentz, SR1
Abdelwahab, HW1
Shaltout, SW1
Sayed Ahmed, HA1
Fouad, AM1
Merrell, E1
Riley, JB1
Salama, R1
Abdelrahman, AG1
Darling, E1
Fadel, G1
Elfar, MSA1
Sabry, K1
Shah, J1
Amin, H1
Nieman, GF1
Mishriky, A1
Aiash, H1
Antunes de Brito, CA1
de Oliveira Filho, JRB1
Marques, DT1
Lencastre, MDC1
de Almeida, JR1
Lopes, EP1
Xiang, E1
Ahuja, T1
Raco, V1
Cirrone, F1
Green, D2
Papadopoulos, J1
Tognon, M1
Darbellay Farhoumand, P1
Blondon, M1
Agoritsas, T1
Kumar Jha, R1
Bansal, S1
S Issar, H1
Chaudhary, M1
Cao, F1
Liu, G1
Wang, W1
Wang, B1
Wei, X1
Lu, F1
Yang, F1
Kang, K1
Wang, Y1
Yang, J1
Qin, K1
Zhao, D1
Cosgrove, RH1
Basken, RL1
Smith, RG1
Hsu, CH1
Kazui, T1
Martinez, BK1
Burt, RW1
Crawford, ES1
Lick, SD1
Khalpey, Z1
Israel, EN1
Thomas, CA1
Mastropietro, CW1
Peetermans, M1
Liesenborghs, L1
Peerlinck, K1
Wijngaerden, EV1
Gheysens, O1
Goffin, KE1
Hoylaerts, MF1
Jacquemin, M1
Verhaegen, J1
Peetermans, WE1
Vanassche, T1
Lindquist, DE1
Stewart, DW1
Brewster, A1
Waldroup, C1
Odle, BL1
Burchette, JE1
El-Bazouni, H1
Gill-Schuster, D1
Bergold, M1
Holzer, L1
Jandial, A1
Mishra, K1
Kumar, S1
Malhotra, P1
Guimicheva, B1
Patel, JP1
Roberts, LN1
Subramanian, D1
Arya, R1
Young, J1
Sawyer, J2
Jenkins, M1
O'Brien, M1
Luchtman-Jones, L1
Breese, EH1
Chamoun, N1
Ghanem, H1
Hachem, A1
Hariri, E1
Lteif, C1
Mansour, H1
Dimassi, H1
Zalloum, R1
Ghanem, G1
Tadic, M1
Belyavskiy, E1
Cuspidi, C1
Pieske, B1
Haßfeld, S1
Voudris, V1
Georgiadou, P1
Kalogris, P1
Kostelidou, T1
Karabinis, A1
Gerotziafas, G1
Gezelius, E1
Bendahl, PO1
Gonçalves de Oliveira, K1
Ek, L1
Bergman, B1
Sundberg, J1
Strandberg, K1
Krämer, R1
Belting, M1
Brouwers, JRBJ1
Roeters van Lennep, JE1
Beinema, MJ1
Guenther, F1
Herr, N1
Mauler, M1
Witsch, T1
Roming, F1
Hein, L1
Boeynaems, JM1
Robaye, B1
Idzko, M1
Bode, C1
Von Zur Muhlen, C1
Robinson, S1
Zincuk, A1
Larsen, UL1
Ekstrøm, C1
Nybo, M1
Rasmussen, B1
Toft, P1
Ladha, A1
Alam, A1
Idestrup, C1
Choi, S1
Seijo, S1
Garcia-Pagan, JC1
Grieco, A1
Lombardo, A1
Biolato, M1
Kaeberich, A2
Raaz, U3
Vogt, A1
Maedgefessel, L1
Neuhart, E1
Krezel, C1
Drouget, L1
Hauroeder, B5
Buerke, M6
Werdan, K5
Schlitt, A6
Bramham, K1
Retter, A1
Robinson, SE1
Mitchell, M1
Moore, GW1
Hunt, BJ4
Sinan, UY1
Coskun, U1
Balaban Kocas, B1
Gultekin, N1
Gurmen, T1
Kucukoglu, S1
Hiscock, RJ1
Casey, E1
Simmons, SW1
Walker, SP1
Newell, PA1
Yusen, RD1
Hull, RD1
Schellong, SM1
Tapson, VF1
Samama, MM3
Chen, M1
Deslandes, B1
Turpie, AG2
Hirsh, J2
Ginsberg, JS1
Chan, N1
Guyatt, G1
Corder, A1
Held, K1
Oschman, A1
Garcipérez de Vargas, FJ1
Marcos, G1
Moyano Calvente, SL1
Giannini, EG1
Stravitz, RT1
Caldwell, SH1
Bytsaĭ, AN1
Chapelle, C1
Bertoletti, L1
Lega, JC1
Cucherat, M1
Zufferey, PJ1
Darmon, JY1
Hallbergson, A1
Gillespie, MJ1
Dori, Y1
Connors, JM2
Oliveira, SN2
Santos, GR1
Glauser, BF3
Capillé, NV1
Queiroz, IN1
Pereira, MS3
Pomin, VH1
Mourão, PA3
Tronina, O1
Mikołajczyk, N1
Pietrzak, B1
Pacholczyk, M1
Durlik, M1
Kremers, RM1
Peters, TC1
Wagenvoord, RJ1
Betancur-Gutiérrez, A1
Bayón-Fernández, J1
García-Rodríguez, MÁ1
García-Egido, A1
Garrote-Coloma, C1
Fernández-Vázquez, F1
Sauer, S1
Goltz, JP1
Gassenmaier, T1
Kunz, AS1
Bley, TA1
Klein, D1
Petritsch, B1
Al-Sallami, HS1
Medlicott, NJ1
Vazquez, FJ1
Paulin, P1
Rodriguez, P1
Lubertino, M1
Gándara, E1
White, DC1
Grines, CL1
Grines, LL1
Marcovitz, P1
Messenger, J1
Schreiber, T1
Vázquez-Alonso, E1
Fábregas, N1
Rama-Maceiras, P1
Ingelmo Ingelmo, I1
Valero Castell, R1
Valencia Sola, L1
Iturri Clavero, F1
Baquero-Salamanca, M1
Téllez-Arévalo, AM1
Calderon-Ospina, C1
Goldsmith, R1
Chan, AK4
Paes, BA1
Bhatt, MD1
Ardillon, L1
Lambert, C1
Eeckhoudt, S1
Boon, LM1
Hermans, C1
Rousseau, A1
Van Dreden, P1
Mbemba, E1
Elalamy, I1
Larsen, A1
Gerotziafas, GT1
Boettcher, M1
Fuchs, TA1
Schäfer, H1
Appl, B1
Trochimiuk, M1
Jiménez-Alcázar, M1
Tiemann, B1
Jung, R1
Bergholz, R1
Reinshagen, K1
Eschenburg, G1
Prieto-Torres, L1
Gracia Cazaña, T1
Pastushenko, I1
Morales Moya, AL1
Soria, J1
Ara Martín, M1
Kurtkoti, J1
Bose, B1
Hiremagalur, B1
Sun, J1
Cochrane, T1
Mehta, AY1
Mohammed, BM1
Martin, EJ1
Brophy, DF1
Gailani, D1
Desai, UR1
Weishaupt, C1
Strölin, A1
Kahle, B1
Kreuter, A1
Schneider, SW1
Gerss, J1
Eveslage, M1
Drabik, A1
Goerge, T1
Boon, IS1
Boon, CS1
Kalinin, RE1
Suchkov, IA1
Pshennikov, AS1
Agapov, AB1
Karapurkar, AP1
Singh, R1
Teelala, SM1
Lalla, R1
Gomez Gomez, E1
Campos Hernandez, JP1
Cazalilla, M1
Triviño, F1
Barbudo, J1
Prieto, R1
Requena Tapia, MJ1
Krueger, K1
Schmutz, A1
Zieger, B2
Kalbhenn, J1
Akhtyamov, IF1
Ziatdinov, BG1
Shigaev, ES1
Kalaska, B1
Kaminski, K1
Miklosz, J1
Yusa, SI1
Sokolowska, E1
Blazejczyk, A1
Wietrzyk, J1
Kasacka, I1
Szczubialka, K1
Pawlak, D1
Nowakowska, M1
Mogielnicki, A1
Curnutte, JT1
Gold, A1
Bronson, MD1
Lu, G1
Conley, PB1
Goodman, S1
Leeds, J1
Wiens, BL1
Siegal, DM1
Zotova, E1
Meeks, B1
Nakamya, J1
Lim, WT1
Bos, S1
Potze, W1
Siddiqui, MS1
Boyett, SL1
Adelmeijer, J1
Daita, K1
Lisman, T1
Sanyal, AJ1
Maegdefessel, L4
Schubert, S3
Reindl, I2
Michel, T1
Carter, JM2
Peetz, D3
Bozcali, E1
Tutpinar, Y1
Scherr, D1
Dalal, D1
Chilukuri, K1
Dong, J1
Spragg, D1
Henrikson, CA1
Nazarian, S1
Cheng, A1
Berger, RD1
Abraham, TP1
Calkins, H1
Marine, JE1
Bauman, ME1
Belletrutti, MJ1
Bajzar, L1
Black, KL1
Kuhle, S1
Bauman, ML1
Patricia Massicotte, M1
Stiefelhagen, P1
Arellano-Rodrigo, E1
Gironella, M1
Nicolau, I1
Vila, M1
Alexander, KP1
Manoukian, SV1
Bertrand, ME1
Feit, F1
White, HD2
Pollack, CV1
Hoekstra, J1
Gersh, BJ1
Ohman, EM2
Venkateswaran, L1
Scaglia, F1
McLin, V1
Hertel, P1
Shchelochkov, OA1
Karpen, S1
Mahoney, D1
Yee, DL1
Miesbach, W1
Galanakis, D1
Scharrer, I1
Ruiz-Irastorza, G1
Martinez-Berriotxoa, A1
Egurbide, MV1
Teixeira, OH1
Mehta, AV1
Viskov, C2
Just, M1
Laux, V3
Mourier, P1
Lorenz, M1
Cage, TA1
Lamborn, KR1
Ware, ML1
Frankfurt, A1
Chakalian, L1
Berger, MS1
McDermott, MW1
Díez, JG1
Medina, HM1
Cheong, BY1
O'Meallie, L1
Ferguson, JJ1
Parsi, K1
Exner, T1
Low, J1
Ma, DD1
Joseph, JE1
Busshardt, M2
Plehn, A2
Roffi, M1
Eberli, FR1
Barbetseas, J1
Tsiachris, D1
Chrysohoou, C1
Brilli, S1
Bonou, M1
Stefanadis, C1
Myers, DD1
Wrobleski, SK1
Deatrick, KB1
Londy, FJ1
Rectenwald, JE1
Henke, PK1
Schaub, RG1
Wakefield, TW1
Warkentin, TE2
Cook, RJ1
Marder, VJ1
Greinacher, A2
Shavit, L1
Lifschitz, M1
Lee, S1
Slotki, I1
Wallace, TW1
Atwater, BD1
Daubert, JP1
Voora, D1
Crowley, AL1
Bahnson, TD1
Hranitzky, PM1
Russ, M2
Ebelt, H2
Sanchez de Toledo, J1
Gunawardena, S1
Munoz, R1
Orr, R1
Berry, D1
Sonderman, S1
Krallman, S1
Shiderly, D1
Wang, L1
Wearden, P1
Morell, VO1
Chrysostomou, C1
Tonbul, A1
Uras, N1
Tayman, C1
Halici, T1
Polat, A1
Mansur Tatli, M1
Schiele, F1
Chin, SO1
Lee, JJ1
Hwang, YH1
Han, JJ1
Maeng, CH1
Baek, SK1
Choi, CW1
Scholey, GM1
Saayman, AG1
Hingston, CD1
Wise, MP1
Al-Sallami, H1
Jordan, S1
Ferguson, R1
Medlicott, N1
Schollum, J1
Duffull, S1
Akcay, AB1
Yuce, M1
Akcay, M1
Sen, N1
Soydinc, HE1
Davutoglu, V1
Zhang, H1
Löwenberg, EC1
Crosby, JR1
MacLeod, AR1
Zhao, C1
Gao, D1
Black, C1
Revenko, AS1
Meijers, JC1
Stroes, ES1
Monia, BP1
dos Reis Macedo, LG1
de Oliveira, L1
Pintão, MC1
Garcia, AA1
Leithäuser, B1
Kasch, F1
Broemel, T1
Park, JW1
Ilhan, E1
Demirci, D1
Güvenç, TS1
Calık, AN1
Ferres, MA1
Olivarez, SA1
Trinh, V1
Davidson, C1
Sangi-Haghpeykar, H1
Aagaard-Tillery, KM1
Pandey, V1
Dummula, K1
Parimi, P1
Huang, L1
Kanellis, J1
Mulley, W1
McKellar, SH1
Abel, S1
Camp, CL1
Suri, RM1
Ereth, MH1
Schaff, HV1
Allana, AM1
Teo, LL1
Chuah, BY1
Liu, TC1
Cheah, WK1
Karow, A1
Hainmann, I1
Nakamura, L1
Budde, U1
Stock, SJ1
Walker, MC1
Edelshain, BT1
Horn, L1
Norman, JE1
Denison, FC1
Vairo, BC2
Oliveira, CP1
Cinelli, LP2
Delbeck, M1
Nickel, KF1
Perzborn, E1
Ellinghaus, P1
Strassburger, J1
Kast, R1
Schäfer, S1
Schermuly, RT1
von Degenfeld, G1
Gulati, A1
Faed, JM1
Isbister, GK1
Duffull, SB1
Clark, ER1
English, JC1
Yau, JW1
Stafford, AR1
Liao, P1
Roberts, R1
Kulik, A1
Saltzman, MB1
Morris, JJ1
Iwatsuki, Y1
Sato, T1
Moritani, Y1
Shigenaga, T1
Suzuki, M1
Kawasaki, T2
Funatsu, T1
Kaku, S1
Argiriou, ME1
Peled, E1
Rovitsky, A1
Axelman, E1
Norman, D1
Brenner, B3
Lulic-Botica, M1
Rajpurkar, M1
Sabo, C1
Tutag-Lehr, V1
Natarajan, G1
Yurttutan, S1
Ozdemir, R1
Erdeve, O1
Calisici, E1
Oncel, MY1
Oguz, SS1
Dilmen, U1
Cakmak, HA1
Değirmenci, E1
Ikizceli, I1
Manlhiot, C1
Brandão, LR2
Kwok, J1
Kegel, S1
Menjak, IB1
Carew, CL1
Schwartz, SM1
Sivarajan, VB1
Caldarone, CA1
Van Arsdell, GS1
McCrindle, BW1
Stief, T1
Yazbek, MA1
Velho, P1
Nadruz, W1
Mahayri, N1
Appenzeller, S1
Costallat, LT1
Shorr, AF2
Eriksson, BI2
Jaffer, AK1
Smith, J1
Zakrzewski, D1
Michałek, P1
Shin, JH1
Kim, GN1
Kil, HR1
Chang, MY1
D'Ippolito, S1
Di Nicuolo, F1
Marana, R1
Castellani, R1
Stinson, J1
Tersigni, C1
Scambia, G1
Di Simone, N1
Villa, E2
Cammà, C2
Marietta, M2
Luongo, M1
Critelli, R1
Colopi, S1
Tata, C1
Zecchini, R1
Gitto, S1
Petta, S1
Lei, B1
Bernabucci, V1
Vukotic, R1
De Maria, N1
Schepis, F1
Karampatou, A1
Caporali, C1
Simoni, L1
Del Buono, M1
Zambotto, B1
Turola, E1
Fornaciari, G1
Schianchi, S1
Ferrari, A1
Valla, D2
Danguy, C1
Biston, P1
Carlier, E1
Defrance, P1
Piagnerelli, M1
Barbarash, LS1
Burkov, NN1
Kudriavtseva, IuA1
Anufriev, AI1
Zhuravleva, IIu1
Teoh, KC1
Lingaratnam, S1
Kirsa, S1
Mellor, JD1
Fontana, RJ1
Yildiz, M1
Karakoyun, S1
Acar, RD1
Gouya, G1
Palkovits, S1
Kapiotis, S2
Madl, C1
Locker, G1
Stella, A1
Wolzt, M1
Heinz, G1
Senzolo, M1
Caldwell, S1
Lima, MA1
Herman, F1
Gray, AL1
de Farias, EH1
Cavalheiro, RP1
Sassaki, GL1
Nader, HB1
Bertesi, M1
Rozzi, N1
Cano, MC1
Vallone, S1
Cappi, C1
Pozzi, S1
Torelli, G1
Kokkonen, L1
Anttonen, O1
Voutilainen, S1
Bergmann, JF1
Mouly, S1
Paramo, JC1
Sendzischew, H1
Sivina, M1
Olszowska, A1
Zelichowski, G1
Meurin, P2
Renaud, N2
Weber, H2
Tabet, JY2
Grosdemouge, A2
Bourmayan, C2
Ben Driss, A1
Carp, H1
Dolitzky, M1
Inbal, A1
Hundt, F1
Bickel, C1
Schaefer, I1
Meyer, J1
Rupprecht, HJ2
Bosanquet, N1
Jönsson, B1
Fox, KA1
Colwell, CW2
Gramse, CA2
Hingorani, A2
Ascher, E2
McLintock, C1
North, RA2
Revel-Vilk, S1
Sharathkumar, A1
Massicotte, P2
Marzinotto, V2
Daneman, A1
Dix, D1
Chan, A1
Stouffer, GA1
Pathak, A1
Whinna, HC1
Klingel, R1
Schwarting, A1
Lotz, J1
Eckert, M1
Hohmann, V1
Hafner, G1
Ho, SH1
Wu, JK1
Hamilton, DP1
Dix, DB1
Wadsworth, LD1
Herishanu, Y1
Misgav, M1
Kirgner, I1
Ben-Tal, O1
Eldor, A1
Naparstek, E1
Karnicki, K1
McBane, RD1
Miller, RS1
Leadley, RJ1
Morser, J2
Owen, WG1
Chesebro, JH2
Driss, AB1
Janssen, D2
Dalmora, SL1
Junior, LB1
Vaccari, SF1
Fronza, M1
Renato de Oliveira, P1
Rolim, CM1
Siddiqui, MA1
Wagstaff, AJ1
Madan, M1
Radhakrishnan, S1
Reis, M1
Paradiso-Hardy, FL1
Godin-Edgecombe, M1
Sparling, C1
Phillips, AM1
Shanmugasegaram, S1
Fort, S1
Naqvi, SZ1
Cohen, EA1
Wells, J1
Kossard, S1
McGrath, M2
Cavusoglu, E1
Lakhani, M1
Marmur, JD1
Becker, RC1
Ol'binskaia, LI1
Kolosova, KIu1
Nesterova, SG1
Egorova, TD1
Fedorova, AIu1
Daykin, HJ1
Sturgeon, SA1
Jones, C1
Wright, CE1
Merkel, N1
Gunther, G1
Schobess, R1
Le Feuvre, C1
Batisse, A1
Collet, JP1
Batisse, JP1
Choussat, R1
Beygui, F1
Helft, G2
Montalescot, G2
Metzger, JP1
Buller, CE1
Pate, GE1
Armstrong, PW1
O'Neill, BJ1
Webb, JG1
Gallo, R2
Welsh, RC1
O'Neill, WW1
Casele, H1
Haney, EI1
James, A1
Rosene-Montella, K1
Carson, M1
Jackson, WL1
Moores, LK1
Ganti, AK1
Vose, JM1
Haire, WD1
Squizzato, A2
Ageno, W2
Cattaneo, A1
Brumana, N1
Byrne, GW1
Davies, WR1
Oi, K1
Rao, VP1
Teotia, SS1
Ricci, D1
Tazelaar, HD1
Walker, RC1
Logan, JS1
McGregor, CG1
Puértolas Ortega, M1
Izquierdo Villarroya, B1
Oliva Perales, P1
Lafuente Ojeda, N1
Izquierdo Villarroya, J1
Ruiz Pérez, R1
Renda, G1
Di Pillo, R1
D'Alleva, A1
Sciartilli, A1
Zimarino, M1
De Candia, E1
Landolfi, R1
Di Giammarco, G1
Calafiore, A1
Criado, PR1
Bernardelli, IM1
Rivitti, EA1
Sotto, MN1
Vilella, MA1
Valente, NY1
Martins, JE1
Cloonan, ME1
DiNapoli, M1
Mousa, SA1
Dahl, OE4
Ogren, M1
Agnelli, G1
Mouret, P1
Rosencher, N1
Bylock, A1
Panfilov, S1
Andersson, M1
Dana, A1
Nguyen, CM1
Cloutier, S1
Barbeau, GR1
Marlovits, S1
Striessnig, G1
Schuster, R1
Stocker, R1
Luxl, M1
Trattnig, S1
Vécsei, V1
Malowany, JI2
Knoppert, DC2
Pepelassis, D1
Lee, DS2
Haran, MZ1
Lichman, I1
Berebbi, A1
Weinmann, E1
Rosenberg, N1
Lemos, PA1
Langford, JR1
Trokhan, S1
Strauss, E1
Wu, J1
McCusker, P1
Massicotte, MP1
Williams, S1
Naumnik, B1
Pawlak, K1
Myśliwiec, M1
Tanne, D1
Katzav, A1
Beilin, O1
Grigoriadis, NC1
Blank, M1
Pick, CG1
Landenberg, Pv1
Shoenfeld, Y1
Chapman, J1
Fernández-Meré, LA1
Fernández Rogríguez, S1
Alvarez-Blanco, M1
Malek, LA1
Chojnowska, L1
Konka, M1
Klopotowski, M1
Skwarek, M1
Maczynska, R1
Hoffman, P1
Ruzyllo, W1
Kropff, SS1
Schmidt, H1
Abbruzzese, TA1
Albadawi, H1
Kang, J1
Patel, VI1
Yoo, JH1
Lamuraglia, GM1
Watkins, MT1
Matthiasson, SE2
Bergqvist, D2
Lundell, A1
Lindblad, B2
Sternlo, JE1
Hybbinette, CH1
Menzin, J1
Colditz, GA1
Regan, MM1
Richner, RE1
Oster, G1
Slunsky, R1
Reach, I1
Thébaud, HE1
Dupuy, CA1
Küntziger, H1
Debure, A1
Fievet, P1
Thoumazou, G1
de Groc, F1
Teboulle, D1
Combe, S1
Rostoker, G1
Durand-Zaleski, I1
Petit-Phar, M1
Ben Maadi, A1
Jazaerli, N1
Radier, C1
Rahmouni, A1
Mathieu, D1
Vasile, N1
Rosso, J1
Przedlacki, J1
Bogdańska-Straszyńska, B1
Sawicka, B1
Włodarczyk, D1
Sladowska, B1
Ajewski, M1
Wasiak, K1
Gellert, R1
Ament, PW1
Bertolino, JG1
Wilson, BA1
Phillips, JK1
Majumdar, G1
Savidge, GF1
Grozovski, ES1
Cohen, JD1
Grunberg, G1
Keslin, J1
Gassner, S1
Stassen, JM1
Lambeir, AM1
Vreys, I1
Deckmyn, H1
Matthyssens, G1
Nyström, A1
Vermylen, J1
Levine, M1
Gent, M1
Leclerc, J1
Anderson, D1
Weitz, J1
Ginsberg, J1
Demers, C1
Kovacs, M1
Gibaldi, M1
Wittkowsky, AK1
Chen, LE2
Seaber, AV2
Korompilias, AV2
Urbaniak, JR2
Samama, CM1
Gigou, F1
Ill, P1
Adams, M1
Brooker, LA1
Andrew, M1
Kalodiki, EP1
Hoppensteadt, DA2
Nicolaides, AN1
Gill, K1
Regan, F1
al-Kutoubi, A1
Cunningham, DA1
Birch, R1
Harris, N1
Hunt, D1
Johnson, J1
Marx, C1
Stone, MH1
Limb, D1
Campbell, P1
Stead, D1
Culleton, G1
Walsh-McMonagle, D1
Horlocker, TT1
Rader, CP1
Kramer, C1
König, A1
Hendrich, C1
Eulert, J1
Gibson, JL1
Ekevall, K1
Walker, I1
Greer, IA3
Warwick, D1
Harrison, J1
Glew, D1
Mitchelmore, A1
Peters, TJ1
Donovan, J1
Kovacs, MJ2
Weir, K1
MacKinnon, K1
Keeney, M1
Brien, WF1
Cruickshank, MK2
Zidar, JP1
Méndez, J1
Sanchís, ME1
de la Fuente, R1
Stolle, R1
Vega, JM1
Martínez, C1
Armentia, A1
Sánchez, P1
Fernández, A1
Gikakis, N1
Rao, AK1
Miyamoto, S1
Gorman, JH1
Khan, MM1
Anderson, HL1
Hack, CE1
Sun, L1
Niewiarowski, S1
Colman, RW1
Edmunds, LH1
Berger, PB1
Bell, MR1
Hasdai, D2
Grill, DE1
Melby, S1
Holmes, DR1
Panchenko, EP1
Bara, L1
Planes, A1
Brennand, JE1
Walker, ID2
Cohen, M1
Laifer, SA1
Casele, HL1
Mallory, R1
Balcezak, T1
Marwick, C1
Lev-Ran, O1
Kramer, A1
Gurevitch, J1
Shapira, I1
Mohr, R1
Dolenska, S1
Younis, JS2
Ohel, G1
Haddad, S1
Lanir, N1
Ben-Ami, M1
Sinha, U1
Ku, P1
Malinowski, J1
Zhu, BY1
Scarborough, RM1
Marlowe, CK1
Wong, PW1
Lin, PH1
Hollenbach, SJ1
Hoffman, R1
Blumenfeld, Z1
Weiner, Z1
Lindqvist, PG1
Dahlbäck, B2
Street, JT1
O'Regan, K1
Wakai, A1
McGuinness, A1
Redmond, HP1
Berndt, N1
Khan, I1
Dunaway, KK1
Gal, P1
Ransom, JL1
Busby, LT1
Weyman, A1
Rodgers, GM1
Olmarker, K1
Rydevik, B1
Racine, E1
Ellison, J2
Thomson, AJ2
Rowan, JA1
McCowan, LM1
Raudkivi, PJ1
Cook, C1
Callaway, M1
McClanahan, TB1
Hicks, GW1
Morrison, AL1
Peng, YW1
Janiczek-Dolphin, N1
Mertz, TE1
Sullivan, ME1
Juneau, PL1
Leadley, R1
Szczepański, M1
Szostek, P1
Pypno, W1
Borówka, A1
Conkie, JA1
McCall, F1
Walker, D1
Greer, A1
Pauzner, R1
Dulitzki, M1
Langevitz, P1
Livneh, A1
Kenett, R1
Many, A1
Barragan, P1
Teuma, X1
Botosezzy, I1
Bouvier, JL1
Comet, B1
Commeau, P1
Macaluso, G1
Roquebert, PO1
Sarasin, FP1
Bounameaux, H1
Kormanová, K1
Krska, Z1
Trca, S1
Pesková, M1
Korínková, P1
Shah, N1
Shah, PS1
De Giorgi, A1
Giannarelli, C1
De Negri, F1
Carmassi, F1
Jeske, W1
Andrassy, K1
Roqué, M1
Rauch, U1
Reis, ED1
Badimon, JJ1
Hiebert, LM2
Wice, SM2
Ping, T1
Herr, D1
Hach-Wunderle, V1
Nakov, R1
Stricker, H1
Mombelli, G1
Pechlaner, C1
Gritsch, W1
Donadini, MP1
Guasti, L1
Bischoff, A1
Han, JM1
Koh, Y1
Kim, SH1
Suh, SY1
Cho, YS1
Yu, SJ1
Yoon, JH1
Gwak, HS1
McClelland, AF1
Mandal, AKJ1
Zakharious, F1
Missouris, CG1
Jonmarker, S1
Hollenberg, J1
Dahlberg, M1
Stackelberg, O1
Litorell, J1
Everhov, ÅH1
Järnbert-Pettersson, H1
Söderberg, M1
Grip, J1
Schandl, A1
Günther, M1
Cronhjort, M1
Iwanaga, T1
Fukushima, R1
Nagasato, T1
Maruyama, I1
Miura, N1
Steenman, F1
Vijlbrief, DC1
Huisman, A1
Bierings, M1
Lutkin, M1
Stronach, L1
Yadav, P1
Hothi, DK1
Woodruff, S1
Lee, AYY1
Carrier, M1
Feugère, G1
Abreu, P1
Heissler, J1
Li, A1
Manohar, PM1
Garcia, DA1
Lyman, GH1
Steuten, LM1
Connell, NT1
DePaula, KM1
deLaorcade, AM1
King, RG1
Hughs, H1
Boudrieau, RJ1
Lauzier, F1
Arnold, DM1
Rabbat, C1
Heels-Ansdell, D2
Zarychanski, R1
Dodek, P1
Ashley, BJ1
Albert, M1
Khwaja, K1
Ostermann, M1
Skrobik, Y1
Fowler, R1
McIntyre, L1
Nates, JL1
Karachi, T2
Zytaruk, N2
Finfer, S1
Cook, D2
Arabi, Y1
Ferguson, N1
Freitag, A1
McDonald, E1
Clarke, F1
Keenan, S1
Pagliarello, G1
Plaxton, W1
Herridge, M1
Vallance, S1
Cade, J1
Crozier, T1
Alves da Silva, S1
Costa Filho, R1
Brandao, N1
Watpool, I1
McArdle, T1
Hollinger, G1
Mandourah, Y1
Al-Hazmi, M1
Adhikari, NK1
Babilonia, KM1
Golightly, LK1
Gutman, JA1
Hassell, KL1
Kaiser, JN1
Kiser, TH1
Klem, PM1
Trujillo, TC1
Shaya, SA1
Saldanha, LJ1
Vaezzadeh, N1
Zhou, J1
Ni, R1
Gross, PL1
Wackernagel, D1
Obaya, S1
Nydert, P1
Gerdsen, F1
Luxembourg, B1
Langer, F1
Bauersachs, R1
Lindhoff-Last, E1
Niemi, T1
Silvasti-Lundell, M1
Armstrong, E1
Hernesniemi, J1
De Cicco, M1
Matovic, M1
Balestreri, L1
Steffan, A1
Pacenzia, R1
Malafronte, M1
Fantin, D1
Bertuzzi, CA1
Fabiani, F1
Morassut, S1
Bidoli, E1
Veronesi, A1
Nassiri, AA1
Hakemi, MS1
Soulati, M1
Marashian, M1
Rahbar, K1
Azizi, F1
Uchikawa, Y1
Ikegami, T1
Masuda, Y1
Ohno, Y1
Mita, A1
Urata, K1
Nakazawa, Y1
Terada, M1
Miyagawa, S1
Pehrsson, S1
Johansson, K1
Kjaer, M1
Elg, M2
Kunitada, S1
Oursin, A1
Depasse, F2
Heptinstall, S1
Pokrovskiĭ, AV1
Gontarenko, VN1
Titova, MI1
Ilicki, J1
Krauss, W1
Andersson, SO1
Nagathan, DS1
Pahwa, HS1
Kumar, A1
Goel, A1
Carlsson, S1
Mattsson, C1
Bick, RL4
Alfar, H1
Goedecke, C1
Stone, S1
Seed, PT1
Parmar, K1
Khamashta, MA1
Poston, L1
Malm, K1
Arnljots, B1
Pleil, AM1
Arnesen, H2
Aspelin, T2
Seljeflot, I1
Kierulf, P1
Lyberg, T1
Gattens, M1
Khamashta, M1
Nelson-Piercy, C1
Almeida, A1
Lersch, C1
Kotowa, W1
Fung, S1
Hiller, E1
Ezekowitz, MD1
Tincani, E1
Piccoli, M1
Turrini, F1
Crowther, MA1
Melotti, G1
Bondi, M1
Ziai, F1
Benesch, T1
Kodras, K1
Neumann, I1
Dimopoulos-Xicki, L1
Haas, M1
Korenkov, M1
Depta, A1
Kentner, R1
Beck, J1
Junginger, T1
Lapidus, LJ1
Rosfors, S1
Ponzer, S1
Levander, C1
Elvin, A1
Lärfars, G1
de Bri, E1
Mätzsch, T1
Holst, J1
Bagge, L2
Wahlberg, T2
Holmer, E2
Tydén, H2
Nyström, SO2
Malm, T1
Kornowski, R1
Glikson, M1
Chernine, A1
Ohad, D1
Battler, A1
Jeffrey, RF1
Khan, AA1
Douglas, JT1
Will, EJ1
Davison, AM1
Tazawa, S1
Ichikawa, K1
Misawa, K1
Fukuyama, J1
Hamano, S1
Miyata, H1
Sakuragawa, N1
Sigüenza, F1
Maduell, F1
Perella, M1
Lopez-Menchero, R1
Grau, E1
Pastor, E1
Schumacher, WA1
Heran, CL1
Steinbacher, TE1
Luomanmäki, K1
Grankvist, S1
Hallert, C1
Jauro, I1
Ketola, K1
Kim, HC1
Kiviniemi, H1
Koskivirta, H1
Sörskog, L1
Vilkko, P1
Partsch, H1
Kechavarz, B1
Mostbeck, A1
Köhn, H1
Lipp, C1
Lindmarker, P1
Holmström, M1
Andreassen, G1
Müller, C1
Mathiesen, P1
Nyhus, S1
Abdelnoor, M1
Solhaug, JH1
Kontny, F1
Dale, J1
Abildgaard, U1
Pedersen, TR1
Pan, M1
Suárez de Lezo, J1
Medina, A1
Romero, M1
Hernández, E1
Segura, J1
Melian, F1
Wangüemert, F1
Landin, M1
Benítez, F1
Amat, M1
Velasco, F1
Torres, A1
Sato, K1
Hisamichi, N1
Taniuchi, Y1
Hirayama, F1
Koshio, H1
Matsumoto, Y1
Ting, SB1
Ziegenbein, RW1
Gan, TE1
Catalano, JV1
Silvers, J1
Chambers, FE1
Ng, S1
McGrath, BP1
Blombäck, M2
Bremme, K2
Hellgren, M2
Siegbahn, A1
Lindberg, H2
Lassen, MR1
Borris, LC1
Anderson, BS1
Jensen, HP1
Skejø Bro, HP1
Andersen, G1
Petersen, AO1
Siem, P1
Hørlyck, E1
Jensen, BV1
Thomsen, PB1
Hansen, BR1
Erin-Madsen, J1
Møller, JC1
Rotwitt, L1
Christensen, F1
Nielsen, JB1
Jørgensen, PS1
Paaske, B1
Tørholm, C1
Hvidt, P1
Jensen, NK1
Nielsen, AB1
Appelquist, E1
Tjalve, E1
Chillag, KJ1
Hoek, KJ1
Hofbauer, R1
Moser, D1
Frass, M1
Oberbauer, R1
Kaye, AD1
Wagner, O1
Druml, W1
Pettilä, V1
Kaaja, R1
Leinonen, P1
Ekblad, U1
Kataja, M1
Ikkala, E1
Wong, PC1
Quan, ML1
Crain, EJ1
Watson, CA1
Wexler, RR1
Knabb, RM1
Nohe, N1
Flemmer, A1
Rümler, R1
Praun, M1
Auberger, K1
Rice, J1
Tinmouth, AH1
Morrow, BH1
Moore, PM1
Olsson, E1
Svartling, N1
Asko-Seljavaara, S1
Lassila, R1
Akinosoglou, K1
Savopoulos, C1
Pouliakis, A2
Triantafyllidis, C1
Markatis, E1
Golemi, F1
Liontos, A1
Vadala, C1
Papanikolaou, IC1
Dimakopoulou, V1
Xarras, P1
Varela, K1
Kaiafa, G1
Mitsianis, A1
Chatzistamati, A1
Randou, E1
Savvanis, S1
Pavlaki, M1
Efraimidis, G1
Samaras, V1
Papazoglou, D1
Konstantinidou, A1
Panagopoulos, P1
Milionis, H1
Xynogalos, S1
Simeonidis, D1
Papageorgiou, G1
Charalambakis, N1
Lianos, E1
Mazlimoglou, E1
Liatsos, AN1
Kosmas, C1
Ziras, N1
Frere, C1
Crichi, B1
Rueda-Camino, JA1
Cajfinger, F1
Spiess, N1
Janus, N1
Le Maignan, C1
Marjanovic, Z1
Farge, D1
Amerali, M1
Politou, M1
Karathanos, C1
Chatzis, D1
Latzios, P1
Papakostas, I1
Goumas, K1
Giannoukas, AD1
Jara-Palomares, L1
Solier-Lopez, A1
Elias-Hernandez, T1
Asensio-Cruz, M1
Blasco-Esquivias, I1
Marin-Barrera, L1
de la Borbolla-Artacho, MR1
Praena-Fernandez, JM1
Montero-Romero, E1
Navarro-Herrero, S1
Serrano-Gotarredona, MP1
Sánchez-Díaz, JM1
Palacios, C1
Otero, R1
Musgrave, KM1
Webber, K1
Murphy, P1
Avery, P1
Biss, TT1
Purnell, J1
Abdulla, AN1
Vasanthan, V1
Harten, C1
Kent, WDT1
Wu, IQ1
Tan, CW1
Wong, WH1
Ng, HJ1
Kirwan, CJ1
Baig, ZF1
Platton, S1
MacCullum, PK1
Ashman, N1
Khalifeh, A1
Grantham, J1
Byrne, J1
Murphy, K2
McAuliffe, F2
Byrne, B1
Matikas, A1
Vardakis, N1
Souglakos, J1
Georgoulias, V1
Higgins, M1
Downey, R1
Al-Saran, KA1
Sabry, A1
Taha, M1
Ghafour, MA1
Al Fawzan, F1
Gouin-Thibault, I1
Pautas, E2
Andreux, JP2
Siguret, V2
Hainer, JW1
Sprogel, P1
Lindenstroem, E1
Pinel, C1
Norris, LA2
Bonnar, J2
Smith, MP1
Steer, PJ1
Savidge, G1
Yoneda, M1
Brosnan, JF1
Stevenson, JL1
Choi, SH1
Varki, A1
Megalopoulos, A1
Vasiliadis, K1
Tsachalis, T1
Tsalis, K1
Blouhos, K1
Alexandridou, S1
Betsis, D1
Lausen, I1
Jensen, R1
Wille-Jørgensen, P1
Jørgensen, LN1
Rasmussen, MS1
Lyng, KM1
Andersen, M1
Raaschou, HO1
Hedner, U1
Février, M1
Wipff, C1
Durand-Gasselin, B1
Laurent, M1
d'Urso, M1
Gaussem, P1

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796]Phase 31,473 participants (Actual)Interventional2006-12-31Active, not recruiting
A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)[NCT00203580]Phase 4910 participants Interventional1994-12-31Completed
LITE Study, Appendix A (HOME-LITE), Amendment 6[NCT00203658]Phase 4400 participants Interventional1997-04-30Completed
Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism[NCT02355548]200 participants (Anticipated)Observational2012-12-31Completed
FREEDOM COVID Anticoagulation Strategy Randomized Trial[NCT04512079]Phase 43,460 participants (Actual)Interventional2020-09-08Completed
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial[NCT04400799]Phase 3475 participants (Actual)Interventional2020-06-15Terminated (stopped due to due to results from interim analysis)
Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study[NCT00571649]Phase 38,101 participants (Actual)Interventional2007-12-31Completed
Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk[NCT02111564]Phase 312,024 participants (Actual)Interventional2014-01-07Completed
Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508]Phase 3600 participants (Actual)Interventional2020-07-30Completed
Prevention of Central Venous Catheter-associated Thrombosis in Critically Ill Children: A Multicenter Phase 2b Trial[NCT03003390]Phase 251 participants (Actual)Interventional2017-04-05Terminated (stopped due to Met protocol defined stopping rule for futility)
Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)[NCT04323787]100,000 participants (Anticipated)Observational2020-03-30Recruiting
Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375]60 participants (Anticipated)Interventional2021-04-20Not yet recruiting
Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial[NCT04394377]Phase 4615 participants (Actual)Interventional2020-06-21Completed
Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility[NCT05334615]60 participants (Anticipated)Observational2022-01-21Recruiting
Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function[NCT03158792]Phase 432 participants (Actual)Interventional2015-10-24Completed
Strategies for Anticoagulation During Venovenous ECMO: The SAFE-ECMO Pilot Trial[NCT04997265]30 participants (Anticipated)Interventional2022-05-12Recruiting
Anticoagulation-free VV ECMO for Acute Respiratory Failure: A Pilot Safety and Feasibility Randomized Clinical Trial[NCT04273607]Phase 2/Phase 340 participants (Anticipated)Interventional2022-09-01Recruiting
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928]Phase 3200 participants (Actual)Interventional2017-06-14Active, not recruiting
Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327]Phase 3479 participants (Actual)Interventional2015-04-10Completed
Diagnostic Accuracy of the ATE Score for the Exclusion of Intra-atrial Thrombi Before Catheter Ablation of Atrial Fibrillation: a Confirmatory Study[NCT03455673]3,160 participants (Actual)Observational2018-09-18Completed
The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158]Phase 313,800 participants Interventional2003-08-31Completed
Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523]Phase 113 participants (Actual)Interventional2012-02-09Completed
XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985]Phase 410 participants (Actual)Interventional2015-07-31Terminated
Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis[NCT04874428]Phase 124 participants (Anticipated)Interventional2021-05-19Recruiting
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764]Phase 3200 participants (Anticipated)Interventional2020-05-08Recruiting
Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden[NCT04412304]166 participants (Actual)Observational2020-03-06Completed
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143]Phase 33,659 participants (Actual)Interventional2006-05-31Completed
Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418]28 participants (Actual)Observational2016-02-01Completed
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958]150 participants (Actual)Observational2014-01-31Completed
Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients[NCT04248348]600 participants (Anticipated)Observational2018-12-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related Death up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.4
Enoxaparin5.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and All-cause Mortality up to Day 35 + 6 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)8.6
Enoxaparin9.2

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.7
Enoxaparin2.7

Percentage of Participants With Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days Per mITT Population

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)3.0
Enoxaparin3.1

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 10 + 5 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.5
Enoxaparin3.9

Percentage of Participants With Net Clinical Benefit (Any DVT, Non-fatal PE, VTE-related Death, Plus Major and Clinically Relevant Non-major Bleeding Events) up to Day 35 + 6 Days

Net clinical benefit is a composite of the primary efficacy endpoint (asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death) plus major and clinically relevant non-major bleeding events. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)9.4
Enoxaparin7.8

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Application of a Study Medication Syringe (Day 10 + 5 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin or transfusion of >=2 units of packed RBCs or whole blood or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)2.8
Enoxaparin1.2

Percentage of Participants With the Composite of Treatment Emergent Major Bleeding Events and Non-major Clinically Relevant Bleeding Events up to 2 Days After Last Intake of Any Study Medication (Day 35 + 6 Days)

Major bleeding events were defined as events leading to >=2 g/dL fall in hemoglobin; or transfusion of >= 2 units of packed RBCs (Red blood cells) or whole blood; or leading to death. Non-major bleeding events were defined as overt bleeding not meeting the criteria of major bleeding (NCT00571649)
Timeframe: Up to Day 35 + 6 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.1
Enoxaparin1.7

Percentage of Participants With VTE Combined With All-cause Mortality up to Day 10 + 5 Days

A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and death (VTE-related and not VTE-related). (NCT00571649)
Timeframe: Up to Day 10 + 5 days

InterventionPercentage of participants (Number)
Rivaroxaban (Xarelto, BAY59-7939)4.8
Enoxaparin4.5

Percentage of Participants With All-cause Mortality up to Day 90 + 7 Days

All deaths, including VTE-related deaths, cardiovascular deaths, and other deaths. (NCT00571649)
Timeframe: Up to Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any eventDeath (cardiovascular)Death (other)VTE related death
Enoxaparin6.21.43.71.1
Rivaroxaban (Xarelto, BAY59-7939)6.71.44.31.0

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 10 + 5 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 10 + 5 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.10.22.40.2
Rivaroxaban (Xarelto, BAY59-7939)0.20.22.40.1

Percentage of Participants With Each Component of the Composite Endpoint of VTE (Any DVT, Non Fatal PE) and VTE-related Death up to Day 35 + 6 Days

The components of the composite endpoint include asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death. (NCT00571649)
Timeframe: Up to Day 35 + 6 days

,
InterventionPercentage of participants (Number)
Symptomatic non-fatal PESymptomatic DVT in lower extremityAsymptomatic proximal DVT in lower extremityVTE related death
Enoxaparin0.50.54.41.0
Rivaroxaban (Xarelto, BAY59-7939)0.30.43.50.6

Percentage of Participants With Major Vascular Events up to Days 10, 35, and 90

Major vascular events included cardiovascular death, acute myocardial infarction (MI), or acute ischemic stroke. Participants may have had a vascular event in more than one category. (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
Any event-Day 10Ischemic stroke-Day 10Acute MI-Day 10Death (cardiovascular)-Day 10Any event-Day 35Ischemic stroke-Day 35Acute MI-Day 35Death (cardiovascular)-Day 35Any event-Day 90Ischemic stroke-Day 90Acute MI-Day 90Death (cardiovascular)-Day 90
Enoxaparin1.00.30.40.41.60.50.50.82.81.10.71.4
Rivaroxaban (Xarelto, BAY59-7939)1.00.30.50.41.80.50.60.92.80.80.91.4

Percentage of Participants With Symptomatic VTE, Including and Excluding VTE-related Death up to Days 10, 35, and 90

Symptomatic VTE (non-fatal PE and DVT in lower extremity), including and excluding VTE-related death (PE and PE cannot be excluded) up to Days 10, 35, and 90 (NCT00571649)
Timeframe: At Day 10 + 5 days, at Day 35 + 6 days, and at Day 90 + 7 days

,
InterventionPercentage of participants (Number)
symptomatic VTE (incl. VTE-related death)-Day 10symptomatic VTE (non fatal)-Day 10symptomatic VTE (incl. VTE-related death)-Day 35symptomatic VTE (non fatal)-Day 35symptomatic VTE (incl. VTE-related death)-Day 90symptomatic VTE (non fatal)-Day 90
Enoxaparin0.60.31.40.71.90.9
Rivaroxaban (Xarelto, BAY59-7939)0.70.51.00.61.70.7

Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to first occurrence of ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.19
Placebo1.49

Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC

Event rate based on time from randomization to first occurrence of VTE-related death (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.72
Placebo0.77

Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE and ACM (adjudicated by CEC) was assessed. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.31
Placebo1.80

Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a composite of symptomatic VTE (lower extremity DVT and non-fatal PE), MI, non-hemorrhagic stroke, and CV death (death due to a known CV cause and death in which a CV cause cannot be ruled out; by this definition, a VTE-related death was considered a CV death) as adjudicated by CEC was reported. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg1.58
Placebo2.03

Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC

Event rate based on time from randomization to the first occurrence of a symptomatic VTE (adjudicated by CEC) was assessed. Symptomatic VTE included lower extremity DVT and non-fatal PE. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.19
Placebo0.42

Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC

A major bleeding event was defined using validated International Society on Thrombosis and Haemostasis (ISTH) bleeding criteria. A major bleeding event was defined as overt bleeding that was associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or a critical site defined as intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or a fatal outcome. Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or last dose + 2 days. (NCT02111564)
Timeframe: From randomization to 2 days after the last dose (Day 45)

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.28
Placebo0.15

Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)

Symptomatic VTE included lower extremity deep vein thrombosis (DVT) and non-fatal pulmonary embolism (PE). Event rate was defined as number of events per 100 participants in 45 days of follow up. Participants who did not have events were censored on the minimum of last visit before or on death, or Day 45. (NCT02111564)
Timeframe: Up to Day 45

InterventionEvents per 100 participants in 45 days (Number)
Rivaroxaban 10 mg or 7.5 mg0.84
Placebo1.11

Length of Stay in the Hospital

Duration of stay in the hospital from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the hospital, an average of 18 days

Interventiondays (Median)
Prophylaxis With Enoxaparin16
Control Arm16

Length of Stay in the Pediatric Intensive Care Unit in Days

Duration of stay in the pediatric intensive care unit from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the pediatric intensive care unit, an average of 10 days

Interventiondays (Median)
Prophylaxis With Enoxaparin12
Control Arm8

Number of Children With Ultrasound

Number of children in whom ultrasound was not performed. (NCT03003390)
Timeframe: Up to 24 hours after removal of CVC

InterventionParticipants (Count of Participants)
All Enrolled Children47

Number of Enrolled Eligible Children

Number of eligible children enrolled in the study. (NCT03003390)
Timeframe: Up to 24 hours after insertion of CVC

InterventionParticipants (Count of Participants)
Eligible Children51

Number of Missed Doses of Enoxaparin

Number of doses of enoxaparin that were not administered. This outcome measure was only applicable to the enoxaparin arm. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days

InterventionDoses of enoxaparin (Number)
Prophylaxis With Enoxaparin8

Number of Mortality

In-hospital mortality during the subject's admission (NCT03003390)
Timeframe: Up to day of discharge from the hospital, average of 18 days

InterventionParticipants (Count of Participants)
Prophylaxis With Enoxaparin5
Control Arm2

Number of Participants With Central Venous Catheter (CVC)- Associated Deep Vein Thrombosis (DVT)

Thrombus in the central vein where the CVC was inserted that is clinically suspected then confirmed radiologically, an incidental radiologic finding, or diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days

InterventionParticipants (Count of Participants)
Prophylaxis With Enoxaparin7
Control Arm13

Number With Clinically Relevant Bleeding

Bleeding that is fatal, associated with a decrease in hemoglobin by ≥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or is in the retroperitoneum, pulmonary, intracranial or central nervous system as defined by International Society of Thrombosis and Haemostasis (NCT03003390)
Timeframe: Up to 30 hours after the last enoxaparin dose

InterventionParticipants (Count of Participants)
Prophylaxis With Enoxaparin1
Control Arm0

Number With Laboratory Confirmed Heparin-induced Thrombocytopenia

Heparin-induced thrombocytopenia that is diagnosed with a positive serotonin release assay (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days

InterventionParticipants (Count of Participants)
Prophylaxis With Enoxaparin0
Control Arm0

Number With Other Thromboembolic Events

Thrombus in the deep vein of any extremity or PE that is clinically suspected then confirmed radiologically, an incidental radiologic finding, excluding DVT diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days

InterventionParticipants (Count of Participants)
Prophylaxis With Enoxaparin1
Control Arm1

Time to 1st Dose of Enoxaparin

Time to first dose of enoxaparin (NCT03003390)
Timeframe: Up to 48 hours after insertion of CVC

Interventionhours from insertion of CVC (Median)
Prophylaxis With Enoxaparin21.1

Time to Target Anti-Xa Activity

Time from insertion of the CVC to time that anti-Xa activity was within 0.2-0.5 IU/mL. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days

Interventionhours from insertion of CVC (Median)
Prophylaxis With Enoxaparin70.4

Endogenous Thrombin Potential

An established measure of coagulation status and is the best method to measure thrombin generation. It directly measures the amount of thrombin generation over time capturing the effects of natural (i.e., subject's coagulation status) and pharmacological (e.g., enoxaparin) pro- and anticoagulants. Endogenous thrombin potential is measured using thrombin generation assay. (NCT03003390)
Timeframe: Day of, day after and day 4 after insertion of the CVC

,
InterventionNanomolar-minute (nM.min) (Median)
Day of CVC InsertionDay After CVC InsertionDay 4 After CVC Insertion
Control Arm1035.6896.58969.89
Prophylaxis With Enoxaparin919.7851.19826.97

Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor

Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

InterventionPercent Change (Median)
FXa Inhibitor: Apixaban-93.3
FXa Inhibitor: Rivaroxaban-94.1
FXa Inhibitor: Edoxaban-71.3
FXa Inhibitor: Enoxaparin-75.41
FXa Inhibitor: Rivaroxaban - Additional Participants-96.3

Participants Achieving Hemostatic Efficacy

Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)

,,,,,,,,,,,,,
InterventionParticipants (Count of Participants)
Excellent/GoodPoor/None
Andexanet: High Dose5417
Andexanet: High Dose - Additional Participant10
Andexanet: Low Dose21851
Andexanet: Low Dose - Additional Participant10
Bleed Type: Gastrointestinal6113
Bleed Type: Intracranial Hemorrhage19351
Bleed Type: Intracranial Hemorrhage - Additional Participants20
Bleed Type: Other184
FXa Inhibitor: Apixaban13435
FXa Inhibitor: Edoxaban226
FXa Inhibitor: Enoxaparin142
FXa Inhibitor: Rivaroxaban10225
FXa Inhibitor: Rivaroxaban - Additional Participants20
Overall27268

Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

InterventionPercent Change (Median)
Excellent/Good
FXa Inhibitor: Rivaroxaban - Additional Participants-96.3

Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy

This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)

,,,
InterventionPercent Change (Median)
Excellent/GoodPoor/None
FXa Inhibitor: Apixaban-93.4-93.3
FXa Inhibitor: Edoxaban-75.8-65.2
FXa Inhibitor: Enoxaparin-75.20-78.44
FXa Inhibitor: Rivaroxaban-94.6-92.4

Number of Patients With Atrial Thrombus and a Zero ATE Score

Patients with atrial thrombus diagnosed by pre-procedural transoesophageal echocardiography, without hypertension, heart failure, history of stroke and a plasma d-dimer level < 270 ng/ml ATE : Atrial Thrombus Exclusion minimum value = 0 maximum value = 4, patient at higher risk of atrial thrombus (NCT03455673)
Timeframe: at most 48 hours before ablation

InterventionParticipants (Count of Participants)
ATE = 0, thrombusATE = 0, No thrombusATE > 0, thrombusATE > 0, No thrombus
Atrial Fibrillation2816272227

Reviews

50 reviews available for dalteparin and Thrombosis

ArticleYear
[Recurrent pulmonary embolism in the functional loss of an LGM cava filter after the recanalization of a caval thrombosis].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1994, Volume: 161, Issue:1

    Topics: Aged; Combined Modality Therapy; Equipment Failure; Femoral Vein; Heparin; Humans; Iliac Vein; Male;

1994
[The treatment of deep venous thrombosis using low-molecular heparin. Swiss Consensus Conference for the Application of Low-molecular Heparin].
    Schweizerische medizinische Wochenschrift, 1994, Feb-05, Volume: 124, Issue:5

    Topics: Animals; Biological Availability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Heparin; Heparin, Low

1994
Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    The Annals of pharmacotherapy, 1998, Volume: 32, Issue:5

    Topics: Blood Platelets; Capillary Permeability; Dalteparin; Enoxaparin; Fibrinolytic Agents; Hemorrhage; He

1998
Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Artery Bypass; Dalteparin; Enoxaparin;

2001
Bemiparin in oncology.
    Drugs, 2010, Dec-14, Volume: 70 Suppl 2

    Topics: Anticoagulants; Antineoplastic Agents; Chemotherapy, Adjuvant; Fibrinolytic Agents; Heparin, Low-Mol

2010
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
    Journal of the American College of Cardiology, 2022, 03-08, Volume: 79, Issue:9

    Topics: Anticoagulants; COVID-19; Critical Care; Enoxaparin; Hospitalization; Humans; Pyrazoles; Pyridones;

2022
Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review.
    Medicine, 2022, Aug-26, Volume: 101, Issue:34

    Topics: Adult; Anticoagulants; Brachiocephalic Veins; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Mal

2022
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Enoxaparin;

2023
[Prevention of thrombosis among medical inpatients : should we adapt enoxaparin doses to the patient's weight ?]
    Revue medicale suisse, 2017, Oct-18, Volume: 13, Issue:579

    Topics: Anticoagulants; Body Weight; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Inpatients; Thrombos

2017
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:11

    Topics: Anticoagulants; Biosimilar Pharmaceuticals; Drug Approval; Enoxaparin; Europe; Humans; Practice Guid

2019
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides.
    Thrombosis and haemostasis, 2014, Volume: 111, Issue:1

    Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Contrast Media; Enoxaparin; Fibrinolytic Agent

2014
Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. Impact on the interpretation of thromboprophylactic effects of new anticoagulant drugs.
    Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3

    Topics: Anticoagulants; Clinical Protocols; Clinical Trials as Topic; Drug Dosage Calculations; Enoxaparin;

2014
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle

2015
[The antiphospholipid syndrome in the 21st century].
    Medicina clinica, 2009, Sep-19, Volume: 133, Issue:10

    Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri

2009
Diabetes and acute coronary syndromes.
    Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia

2009
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
    Thrombosis research, 2010, Volume: 125, Issue:4

    Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen

2010
Current enoxaparin dosing guidelines have dubious credibility.
    The New Zealand medical journal, 2010, Apr-30, Volume: 123, Issue:1313

    Topics: Anticoagulants; Drug Prescriptions; Enoxaparin; Humans; Practice Guidelines as Topic; Thrombosis

2010
Discoveries in thrombosis care for medical patients.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Critical Care; Drug Costs; Enoxaparin; Fibrinolytic

2002
Thromboprophylaxis in medical patients: focus on France.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth

2002
[Enoxaparin in haemodialysis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2002, Volume: 13, Issue:77

    Topics: Anticoagulants; Enoxaparin; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Renal Dialysis; Th

2002
Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    PharmacoEconomics, 2003, Volume: 21, Issue:16

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary

2003
Dosing and timing of low-molecular-weight heparin thromboprophylaxis in total hip arthroplasty.
    Orthopedics, 2003, Volume: 26, Issue:11

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weigh

2003
Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:7

    Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Centra

2004
[Thrombosis prophylaxis with heparins in intensive care patients].
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2005, Volume: 40, Issue:3

    Topics: Age Factors; Anticoagulants; APACHE; Critical Care; Enoxaparin; Heparin; Heparin Antagonists; Hepari

2005
Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
    Drugs, 2005, Volume: 65, Issue:7

    Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Enoxaparin; Hemorrhage; Humans; Thr

2005
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
    Kardiologiia, 2005, Volume: 45, Issue:12

    Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic

2005
A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jan-15, Volume: 44, Issue:2

    Topics: Adult; Anticoagulants; Cytomegalovirus Infections; Enoxaparin; Heparin, Low-Molecular-Weight; Humans

2007
Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates.
    Thrombosis research, 2008, Volume: 122, Issue:6

    Topics: Anticoagulants; Catheters, Indwelling; Enoxaparin; Humans; Infant, Newborn; Infant, Premature; Throm

2008
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Archives of internal medicine, 1995, Apr-10, Volume: 155, Issue:7

    Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi

1995
Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.
    Nephron, 1995, Volume: 69, Issue:1

    Topics: Adult; Biopsy; Cohort Studies; Enoxaparin; Female; Humans; Incidence; Kidney; Male; Middle Aged; Nep

1995
Enoxaparin in the prevention of deep venous thrombosis.
    American family physician, 1994, Volume: 50, Issue:8

    Topics: Clinical Trials as Topic; Drug Costs; Enoxaparin; Hip Prosthesis; Humans; Postoperative Complication

1994
Contemporary use of and future roles for heparin in antithrombotic therapy.
    Journal of clinical pharmacology, 1995, Volume: 35, Issue:11

    Topics: Anticoagulants; Antithrombins; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans;

1995
[Enoxaparin: molecular structure aspects, pharmacokinetics, efficiency in internal medicine].
    Klinicheskaia meditsina, 1998, Volume: 76, Issue:11

    Topics: Adult; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Infarction; Thrombosis

1998
Low molecular weight heparins in the cardiac catheterization laboratory.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants;

1999
Neuroaxial blocks and LMWH thromboprophylaxis.
    Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:12

    Topics: Anesthesia, Epidural; Contraindications; Enoxaparin; Fibrinolytic Agents; Hematoma, Epidural, Crania

1998
Differentiation of the low-molecular-weight heparins.
    Pharmacotherapy, 2001, Volume: 21, Issue:6 Pt 2

    Topics: Dalteparin; Enoxaparin; Fibrinolytic Agents; Half-Life; Heparin, Low-Molecular-Weight; Humans; Molec

2001
[Antithrombotic treatment protocols in interventional cardiology].
    Archives des maladies du coeur et des vaisseaux, 2001, Volume: 94, Issue:11 Suppl

    Topics: Aspirin; Clopidogrel; Drug Resistance; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Myocardial

2001
Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children.
    The Cochrane database of systematic reviews, 2014, Mar-10, Issue:3

    Topics: Adolescent; Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Heparin, Low-M

2014
Pharmacological profile of reviparin-sodium.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Animals; Biological Availability; Blood Coagulation; Carbohydrate Sequence; Factor Xa Inhibitors; He

1993
Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1993, Volume: 4 Suppl 1

    Topics: Biocompatible Materials; Blood Coagulation Tests; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Mol

1993
Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
    Thrombosis research, 1996, Volume: 81, Issue:2 Suppl

    Topics: Anticoagulants; Cost-Benefit Analysis; Heparin, Low-Molecular-Weight; Humans; Postoperative Complica

1996
Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7

    Topics: Clinical Trials as Topic; Drug Evaluation; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Venous

2013
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Thrombosis research, 2019, Volume: 180

    Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridine

2019
[Administration of dalteparin in reconstructive vascular surgery].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2011, Volume: 17, Issue:2

    Topics: Anticoagulants; Arterial Occlusive Diseases; Arteries; Blood Coagulation; Blood Coagulation Factors;

2011
Partial segmental thrombosis of the corpus cavernosum: a case report and a review of the literature.
    Urology, 2012, Volume: 79, Issue:3

    Topics: Adult; Alcoholic Intoxication; Dalteparin; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging;

2012
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:10

    Topics: Aged; Anticoagulants; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; T

2022
Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.
    International journal of clinical practice, 2022, Volume: 2022

    Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Renal Insufficiency; Thrombosis; Tinzaparin

2022
Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin.
    Seminars in thrombosis and hemostasis, 2004, Volume: 30 Suppl 1

    Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Thrombosis; Tinzaparin

2004
An update on heparins at the beginning of the new millennium.
    Seminars in thrombosis and hemostasis, 2000, Volume: 26 Suppl 1

    Topics: Cardiology; Clinical Trials as Topic; Fibrinolytic Agents; Heparin Lyase; Heparin, Low-Molecular-Wei

2000
Development of tinzaparin: a heparinase-digested low-molecular-weight heparin.
    Seminars in thrombosis and hemostasis, 2000, Volume: 26 Suppl 1

    Topics: Animals; Fibrinolytic Agents; Heparin; Heparin Lyase; Heparin, Low-Molecular-Weight; Humans; Thrombo

2000

Trials

94 trials available for dalteparin and Thrombosis

ArticleYear
Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation.
    Artificial organs, 2008, Volume: 32, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Dipyridamole; Heart Failure; Heart-Assist Devices; Heparin; Heparin,

2008
Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Haematologica, 2003, Volume: 88, Issue:1

    Topics: Aged; Anticoagulants; Catheterization, Central Venous; Female; Heparin, Low-Molecular-Weight; Humans

2003
Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis.
    Journal of Korean medical science, 2007, Volume: 22, Issue:2

    Topics: Adult; Coumarins; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Hydrocephalus; Nadro

2007
Prevention of thromboses in human patients with Bothrops lanceolatus envenoming in Martinique: failure of anticoagulants and efficacy of a monospecific antivenom. Research Group on Snake Bites in Martinique.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antivenins; Blood Coagulation; Bothrops; Drug T

1995
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans; Infusions,

1996
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
    Polskie Archiwum Medycyny Wewnetrznej, 1996, Volume: 95, Issue:1

    Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male

1996
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
    Likars'ka sprava, 1999, Issue:5

    Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I

1999
Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi.
    Scandinavian journal of gastroenterology. Supplement, 2001, Issue:234

    Topics: Anticoagulants; Capillaries; Colitis, Ulcerative; Humans; Intestinal Mucosa; Nadroparin; Prospective

2001
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    The Lancet. Haematology, 2022, Volume: 9, Issue:8

    Topics: Aged; COVID-19; Enoxaparin; Female; Humans; Male; Middle Aged; Outpatients; SARS-CoV-2; Thrombosis;

2022
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
    Circulation, 2023, 03-28, Volume: 147, Issue:13

    Topics: Aged; Anticoagulants; Cohort Studies; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhag

2023
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
    PloS one, 2023, Volume: 18, Issue:11

    Topics: Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Gastrointestinal Neoplasms; Humans; Postoper

2023
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; In

2020
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Trials, 2020, Sep-09, Volume: 21, Issue:1

    Topics: Anticoagulants; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Enoxaparin; Eq

2020
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).
    Thrombosis research, 2020, Volume: 196

    Topics: Adult; Aged; Anticoagulants; Brazil; COVID-19; COVID-19 Drug Treatment; Drug Administration Schedule

2020
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
    Thrombosis research, 2020, Volume: 196

    Topics: Anticoagulants; Atorvastatin; COVID-19; COVID-19 Drug Treatment; Critical Illness; Double-Blind Meth

2020
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
    Critical care medicine, 2021, 04-01, Volume: 49, Issue:4

    Topics: Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Critical Illness; Enoxapar

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
    JAMA, 2021, 04-27, Volume: 325, Issue:16

    Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox

2021
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:1

    Topics: Aged; Anticoagulants; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Critical Care; Dose-Respons

2022
Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.
    American heart journal, 2021, Volume: 238

    Topics: Administration, Oral; Anticoagulants; Brazil; COVID-19; Drug Administration Schedule; Enoxaparin; Fi

2021
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
    Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:9

    Topics: Adult; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Male; SARS-CoV-2; Thrombosis

2021
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:5

    Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithro

2018
Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
    BMC pharmacology & toxicology, 2019, 05-07, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Hemorrhage; Humans; Male; Re

2019
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 118

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Blood Coagu

2019
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial.
    Critical care (London, England), 2013, Apr-19, Volume: 17, Issue:2

    Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dose-Response Relationship, Drug; Double-

2013
In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Anticoagulants; Biotin; Cardiac Catheters; Enoxaparin; Factor Xa Inhibitors; Fema

2014
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:6

    Topics: Age Factors; Aged; Anticoagulants; Canada; Enoxaparin; Europe; Female; Follow-Up Studies; Hemorrhage

2013
[Prophylaxis of thrombotic complications in patients after reconstructive operations on the main arteries of the lower extremities, made for arteriosclerosis obliterans in a critical ischemia stage].
    Klinichna khirurhiia, 2014, Issue:2

    Topics: Aged; Anticoagulants; Arteriosclerosis Obliterans; Blood Coagulation; Enoxaparin; Female; Humans; Is

2014
Comparison of the usefulness of enoxaparin versus warfarin for prevention of left ventricular mural thrombus after anterior wall acute myocardial infarction.
    The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anterior Wall Myocardial Infarction; Anticoagulants; Enoxaparin; Fem

2015
Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.
    Nephrology (Carlton, Vic.), 2016, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cross-Over Stud

2016
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:2

    Topics: Administration, Oral; Adult; Aged; Enoxaparin; Factor Xa Inhibitors; Female; Germany; Humans; Male;

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    The New England journal of medicine, 2016, 09-22, Volume: 375, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In

2016
Comparison of bivalirudin, enoxaparin, and unfractionated heparin in preventing cardiac catheter thrombosis. Results of an in-vitro study.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Eptifibatide; Erythrocytes; Fibrin; Fi

2008
Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Journal of the American College of Cardiology, 2009, Mar-24, Volume: 53, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aging; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Arter

2009
Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
    Thrombosis research, 2012, Volume: 130, Issue:1

    Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Glucuronidase; Hip; Humans; Knee; Male; Middle

2012
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
    Gastroenterology, 2012, Volume: 143, Issue:5

    Topics: Anticoagulants; Bacterial Infections; Bacterial Translocation; Biomarkers; DNA, Bacterial; Enoxapari

2012
Bioactivity of enoxaparin in critically ill patients with normal renal function.
    British journal of clinical pharmacology, 2012, Volume: 74, Issue:5

    Topics: Adult; Aged; Anticoagulants; Case-Control Studies; Critical Illness; Enoxaparin; Factor Xa Inhibitor

2012
[Treatment of left intraventricular thrombosis with low molecular weight heparin].
    Archives des maladies du coeur et des vaisseaux, 2003, Volume: 96, Issue:4

    Topics: Aged; Anticoagulants; Echocardiography; Enoxaparin; Feasibility Studies; Female; Heparin, Low-Molecu

2003
Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:3

    Topics: Abortion, Habitual; Adult; Birth Rate; Enoxaparin; Family Health; Female; Fibrinolytic Agents; Human

2003
Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Kidney & blood pressure research, 2004, Volume: 27, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Kidney Failur

2004
Treatment of left ventricular thrombi with a low molecular weight heparin.
    International journal of cardiology, 2005, Feb-15, Volume: 98, Issue:2

    Topics: Anticoagulants; Enoxaparin; Female; Heart Diseases; Heart Ventricles; Humans; Male; Middle Aged; Pro

2005
Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    The American journal of cardiology, 2005, Jun-01, Volume: 95, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Drug Therapy, Combination; Elective Surgical P

2005
Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients.
    Acta haematologica, 2006, Volume: 115, Issue:3-4

    Topics: Adolescent; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Hum

2006
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2006, Volume: 67, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angio

2006
Bone density changes in women who receive thromboprophylaxis in pregnancy.
    American journal of obstetrics and gynecology, 2006, Volume: 195, Issue:4

    Topics: Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Heparin; Humans; Pregnancy; Prospective Stu

2006
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypass;

2007
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
    Pathophysiology of haemostasis and thrombosis, 2006, Volume: 35, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast

2006
Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association, 2007, Volume: 23, Issue:7

    Topics: Adult; Anterior Cruciate Ligament; Anticoagulants; Arthroscopy; Double-Blind Method; Drug Administra

2007
Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Thrombosis research, 2009, Volume: 123, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Cross-Over Studies; Enoxaparin; Fe

2009
Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.
    Clinical orthopaedics and related research, 1995, Issue:319

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female

1995
Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Archives of internal medicine, 1995, Apr-10, Volume: 155, Issue:7

    Topics: Cost-Benefit Analysis; Decision Trees; Enoxaparin; Hip Prosthesis; Humans; Pulmonary Embolism; Sensi

1995
[Optimization of enoxaparin dose in the prevention of coagulation in the circuits of hemodialysis: results of a multicenter study].
    Nephrologie, 1994, Volume: 15, Issue:6

    Topics: Adult; Aged; Enoxaparin; Female; Humans; Male; Middle Aged; Renal Dialysis; Thrombosis

1994
Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.
    Nephron, 1995, Volume: 69, Issue:1

    Topics: Adult; Biopsy; Cohort Studies; Enoxaparin; Female; Humans; Incidence; Kidney; Male; Middle Aged; Nep

1995
[Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
    Polskie Archiwum Medycyny Wewnetrznej, 1994, Volume: 91, Issue:6

    Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Enoxaparin; Extracorporeal Circulation; Female; He

1994
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    The New England journal of medicine, 1996, Mar-14, Volume: 334, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Home Nursing; Hospitalization; Humans

1996
Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group.
    Annals of vascular surgery, 1995, Volume: 9 Suppl

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Vessel Prosthesis; Enoxaparin; Female; Heparin

1995
Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial.
    International angiology : a journal of the International Union of Angiology, 1996, Volume: 15, Issue:2

    Topics: Aged; Anticoagulants; Bandages; Combined Modality Therapy; Double-Blind Method; Enoxaparin; Female;

1996
A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study.
    International orthopaedics, 1996, Volume: 20, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bandages; Enoxaparin; Female; Hip Prosthesis; Humans

1996
Low-molecular-weight heparin and partial thromboplastin time-adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty.
    The Journal of arthroplasty, 1998, Volume: 13, Issue:2

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged;

1998
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
    British journal of obstetrics and gynaecology, 1998, Volume: 105, Issue:7

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Heparin; Heparin, Low-Molecular-Weight; Hu

1998
Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial.
    The Journal of bone and joint surgery. American volume, 1998, Volume: 80, Issue:8

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Foot; Humans; Male; Middle

1998
Low molecular weight heparin in coronary stenting.
    The Canadian journal of cardiology, 1998, Volume: 14 Suppl E

    Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj

1998
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
    Circulation, 1999, Jan-19, Volume: 99, Issue:2

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra

1999
Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
    British journal of haematology, 1999, Volume: 104, Issue:2

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitor

1999
The lack of effect of a prophylactic dose of enoxaparin on thrombin generation in patients subjected to nephrectomy because of kidney cancer.
    Thrombosis research, 2001, Dec-15, Volume: 104, Issue:6

    Topics: Adult; Aged; Antithrombin III; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Fibrinoly

2001
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:6

    Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto

2001
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:6

    Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D

2001
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Thrombosis and haemostasis, 2002, Volume: 87, Issue:4

    Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal

2002
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    The New England journal of medicine, 2001, Mar-01, Volume: 344, Issue:9

    Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L

2001
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:4

    Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N

2019
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.
    Intensive care medicine, 2013, Volume: 39, Issue:12

    Topics: Critical Care; Dalteparin; Double-Blind Method; Fibrinolytic Agents; Heparin; Humans; Informed Conse

2013
Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:12

    Topics: Acenocoumarol; Aged; Anticoagulants; Catheterization, Central Venous; Dalteparin; Female; Humans; Ma

2009
Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Iranian journal of kidney diseases, 2009, Volume: 3, Issue:3

    Topics: Adult; Aged; Anticoagulants; Aryldialkylphosphatase; Dalteparin; Drug Costs; Female; Heparin; Humans

2009
Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Thrombosis research, 2010, Volume: 126, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Aged; Anticoagulants; Antithrombins; Azetidines; Be

2010
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:5

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Factors; Dalteparin; Female;

2003
Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:8

    Topics: Adult; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Middle Aged; Pregnancy; Preg

2003
Video laparoscopic surgery: is out-of-hospital thromboprophylaxis necessary?
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:2

    Topics: Adult; Aged; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Laparoscopy; Male; Mid

2005
The effect of oral anticoagulation on clotting during hemodialysis.
    Kidney international, 2005, Volume: 68, Issue:2

    Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cross-Over Studies; Dalteparin; Drug

2005
Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
    Journal of orthopaedic trauma, 2007, Volume: 21, Issue:1

    Topics: Achilles Tendon; Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind M

2007
A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis.
    Journal of internal medicine, 1996, Volume: 240, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Dalteparin; Drug Administration Schedule; Female; Fibrinolytic Agent

1996
Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin.
    Journal of vascular surgery, 1996, Volume: 24, Issue:5

    Topics: Aged; Aged, 80 and over; Bandages; Chi-Square Distribution; Dalteparin; Female; Femoral Vein; Fibrin

1996
Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
    Thrombosis and haemostasis, 1997, Volume: 77, Issue:1

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Double-Blind Method; Female; Hip; Hip Prosthesis; Humans; M

1997
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.
    Journal of the American College of Cardiology, 1997, Volume: 30, Issue:4

    Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Embolism; Female; Heart Diseases; Heart Ventr

1997
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
    The American journal of cardiology, 1997, Nov-15, Volume: 80, Issue:10

    Topics: Anticoagulants; Coronary Disease; Dalteparin; Female; Femoral Artery; Hemorrhage; Heparin; Heparin A

1997
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1998, Volume: 9, Issue:1

    Topics: Adult; Dalteparin; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Pregnancy; Pr

1998
Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
    Thrombosis research, 1998, Mar-15, Volume: 89, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Double-B

1998
A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1998, Volume: 9, Issue:4

    Topics: Adult; Anticoagulants; Antithrombin III; Area Under Curve; Circadian Rhythm; Cross-Over Studies; Dal

1998
Effect of anticoagulation on blood membrane interactions during hemodialysis.
    Kidney international, 1999, Volume: 56, Issue:4

    Topics: Adult; Anticoagulants; Blood Coagulation; Cell Adhesion; Citrates; Dalteparin; Erythrocytes; Female;

1999
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
    Thrombosis research, 1999, Nov-15, Volume: 96, Issue:4

    Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular-

1999
Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety--a preliminary report.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5 Suppl 1

    Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Outpatients; Thrombosis;

1999
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
    Circulation, 2000, Nov-28, Volume: 102, Issue:22

    Topics: Adult; Aged; Anticoagulants; Antithrombin III; Cohort Studies; Dalteparin; Dose-Response Relationshi

2000
Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:6

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Feasibility Studies; Female; Hemorrhage; Hospitalization; H

2001
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:8

    Topics: Aged; Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective

2022
Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis.
    Nephron. Clinical practice, 2013, Volume: 123, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Dose-Response Relationship, Drug; Drug M

2013
Colour Doppler flow imaging ultrasonography versus venography as screening method for asymptomatic postoperative deep venous thrombosis.
    European journal of radiology, 1995, Volume: 20, Issue:3

    Topics: Abdomen; Bandages; Elective Surgical Procedures; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Mol

1995

Other Studies

332 other studies available for dalteparin and Thrombosis

ArticleYear
Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.
    Scientific reports, 2022, 10-18, Volume: 12, Issue:1

    Topics: Acute Kidney Injury; Anticoagulants; COVID-19; Critical Illness; Humans; Nadroparin; Prospective Stu

2022
Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multicenter Study.
    ASAIO journal (American Society for Artificial Internal Organs : 1992), 2021, 01-01, Volume: 67, Issue:1

    Topics: Adult; Anticoagulants; Extracorporeal Membrane Oxygenation; Female; Heparin; Humans; Male; Middle Ag

2021
[Prevention of thrombohemorrhagic postoperative complications in patients with benign prostatic hyperplasia].
    Urologiia (Moscow, Russia : 1999), 2017, Issue:1

    Topics: Fibrinolytic Agents; Hemorrhage; Humans; Low-Level Light Therapy; Male; Nadroparin; Postoperative Co

2017
Thrombogenesis in Thrombophilic Pregnancy: Evaluation of Low-Molecular-Weight Heparin Prophylaxis.
    Acta haematologica, 2017, Volume: 137, Issue:4

    Topics: Adult; Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-We

2017
Iatrogenic calcinosis cutis after subcutaneous LMW-heparin administration in a hemodialysis patient.
    International urology and nephrology, 2013, Volume: 45, Issue:4

    Topics: Biopsy, Needle; Calcinosis; Female; Humans; Iatrogenic Disease; Immunohistochemistry; Injections, Su

2013
Effect of acetylsalicylic acid on microvascular thrombosis in autologous breast reconstruction.
    Journal of reconstructive microsurgery, 2014, Volume: 30, Issue:1

    Topics: Adult; Aspirin; Autografts; Fibrinolytic Agents; Humans; Mammaplasty; Middle Aged; Myocutaneous Flap

2014
[Prophylaxis of thrombohemorrhagic complications in surgical treatment of chemoresistant pulmonary tuberculosis].
    Klinichna khirurhiia, 2014, Issue:10

    Topics: Adult; Anticoagulants; Antitubercular Agents; Female; Hemorrhage; Humans; Hydroxyethylrutoside; Indo

2014
[Determination of anti-Xa activity in cancer patients].
    Klinicheskaia laboratornaia diagnostika, 2008, Issue:11

    Topics: Anticoagulants; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Humans; Nadroparin; Neoplasms; Thrombo

2008
Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention.
    Thrombosis research, 2010, Volume: 126, Issue:1

    Topics: Animals; Arteries; Clinical Trials as Topic; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Mal

2010
Successful thrombolysis of late, non-obstructive mitral bioprosthetic valve thrombosis: case report and review of the literature.
    The Journal of heart valve disease, 2011, Volume: 20, Issue:5

    Topics: Acenocoumarol; Aged; Bioprosthesis; Echocardiography, Transesophageal; Female; Fibrinolytic Agents;

2011
Anti-thrombotic effect of a synthetic heparin mimetic in an arterial model of thrombosis in rats: comparison with unfractionated heparin and nadroparin.
    Thrombosis and haemostasis, 2002, Volume: 88, Issue:4

    Topics: Animals; Carotid Arteries; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Nadropari

2002
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
    The American journal of the medical sciences, 2003, Volume: 325, Issue:1

    Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul

2003
Thrombosis of a prosthetic aortic valve during pregnancy despite therapeutic dosage of Nadroparin.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:4

    Topics: Adult; Aortic Valve; Female; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans;

2004
Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study.
    Neurosurgery, 2004, Volume: 55, Issue:5

    Topics: Angiography; Brain; Drug Administration Schedule; Humans; Nadroparin; Postoperative Hemorrhage; Pros

2004
Evaluation of two experimental venous thrombosis models in the rat.
    Thrombosis research, 2005, Volume: 115, Issue:6

    Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemos

2005
Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser.
    Thrombosis research, 1995, Feb-15, Volume: 77, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Indomethacin;

1995
Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Thrombosis and haemostasis, 1994, Volume: 72, Issue:3

    Topics: Animals; Blood Coagulation; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrino

1994
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
    Blood, 1994, Oct-15, Volume: 84, Issue:8

    Topics: Animals; Antithrombin III; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Male; Nadroparin; Oli

1994
[Antithrombotic properties of heparin independent of its anticoagulant activity].
    Acta haematologica Polonica, 1994, Volume: 25, Issue:3

    Topics: Animals; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Heparin; Laser

1994
Derivatives of bis-aldonic acid amides and their anticoagulant and antithrombotic properties.
    Seminars in thrombosis and hemostasis, 1994, Volume: 20, Issue:2

    Topics: Animals; Anticoagulants; Bleeding Time; Disaccharides; Factor Xa Inhibitors; Fibrinolytic Agents; He

1994
Successful treatment of catheter-related sepsis and extraluminal catheter thrombosis with vancomycin and fraxiparin without catheter removal.
    Nephron, 1997, Volume: 75, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Catheterization, Central Venous; Catheters

1997
Calciphylaxis, thrombotic diathesis and defects in coagulation regulation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:5

    Topics: Blood Coagulation Disorders; Calciphylaxis; Disease Susceptibility; Humans; Nadroparin; Protein C; P

1997
[Fraxiparin and prevention of left ventricular thrombosis in non-thrombolyzed myocardial infarction. FRATIV Study].
    Archives des maladies du coeur et des vaisseaux, 1997, Volume: 90, Issue:9

    Topics: Aged; Drug Administration Schedule; Female; Heart Ventricles; Heparin, Low-Molecular-Weight; Humans;

1997
Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.
    Journal of cardiovascular pharmacology, 1999, Volume: 34, Issue:3

    Topics: Animals; Blood Coagulation Factors; Disease Models, Animal; Fibrinolytic Agents; Heparin; Heparinoid

1999
No effect of nadroparin prophylaxis in the prevention of central venous catheter (CVC)-associated thrombosis in bone marrow transplant recipients.
    Bone marrow transplantation, 2000, Volume: 26, Issue:10

    Topics: Bone Marrow Transplantation; Catheterization, Central Venous; Fibrinolytic Agents; Humans; Nadropari

2000
[Ambulatory therapy of thrombosis with low molecular weight heparin. Further simplification by one-time administration].
    MMW Fortschritte der Medizin, 2001, Mar-29, Volume: 143, Issue:13

    Topics: Ambulatory Care; Clinical Trials as Topic; Drug Administration Schedule; Enoxaparin; Humans; Injecti

2001
Clinical experiences with low-molecular weight heparins in pediatric patients.
    Thrombosis research, 2001, Sep-01, Volume: 103, Issue:5

    Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Enoxaparin; Factor Xa Inhibitors; Female; Hepar

2001
[Fraxiparin in the treatment of thrombophilia in angiopathy].
    Terapevticheskii arkhiv, 2001, Volume: 73, Issue:12

    Topics: Adult; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Peripheral Vascular Diseases;

2001
[The use of parnaparin sodium (Fluxum) in the prevention of thromboembolic complications after surgical treatment of fractures associated with high risks of thrombosis].
    Khirurgiia, 2020, Issue:10

    Topics: Anticoagulants; Enoxaparin; Fracture Fixation; Fractures, Bone; Heparin, Low-Molecular-Weight; Human

2020
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
    Thrombosis research, 2020, Volume: 196

    Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; COVID-19; COVID-19 Drug Trea

2020
Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
    International angiology : a journal of the International Union of Angiology, 2004, Volume: 23, Issue:4

    Topics: Carboxypeptidase B2; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Wei

2004
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2022, Volume: 75, Issue:8

    Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post

2022
Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy.
    World neurosurgery, 2019, Volume: 126

    Topics: Animals; Anticoagulants; Antithrombins; Carotid Arteries; Cerebral Revascularization; Dabigatran; He

2019
A prospective cohort study on the effectiveness of 3500 IU versus 5000 IU bemiparin in the prophylaxis of postoperative thrombotic events in obese patients undergoing orthopedic surgery.
    Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:13-14

    Topics: Adult; Aged; Algorithms; Body Weight; Cohort Studies; Female; Follow-Up Studies; Heparin, Low-Molecu

2009
[Hip fracture during pregancy in a woman with transient osteporosis].
    Revista espanola de anestesiologia y reanimacion, 2010, Volume: 57, Issue:5

    Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I

2010
Effect of unfractionated heparin and long-term treatment with low-molecular-weight heparin, bemiparin, on potassium levels.
    Thrombosis and haemostasis, 2005, Volume: 94, Issue:5

    Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Hyperkalemia; Potassium; Thrombosis

2005
Does low molecular weight heparin really protect against prosthetic valve thrombosis during pregnancy with strict anti-Xa monitoring?
    Taiwanese journal of obstetrics & gynecology, 2021, Volume: 60, Issue:5

    Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heparin, Low-Molec

2021
Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:12

    Topics: Anticoagulants; Child; Enoxaparin; Humans; Neoplasms; Thrombosis; Vena Cava, Superior; Venous Thromb

2021
Prophylaxis with low-molecular-weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase.
    British journal of haematology, 2022, Volume: 197, Issue:2

    Topics: Anticoagulants; Asparaginase; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Thrombosis

2022
Comparison of the injection of low-molecular weight heparin in the arterial vs. venous blood line for preventing extracorporeal circuit clotting during hemodialysis.
    Hemodialysis international. International Symposium on Home Hemodialysis, 2022, Volume: 26, Issue:3

    Topics: Anticoagulants; Enoxaparin; Hemodiafiltration; Heparin, Low-Molecular-Weight; Humans; Molecular Weig

2022
Post-operative Anticoagulation Strategy Following Comprehensive Stage 2 Procedure for Single Ventricle Physiology.
    Pediatric cardiology, 2022, Volume: 43, Issue:7

    Topics: Anticoagulants; Blood Coagulation; Child; Enoxaparin; Humans; Infant; Retrospective Studies; Thrombo

2022
Investigating the experience of parents who have given their infants enoxaparin at home.
    Thrombosis research, 2022, Volume: 214

    Topics: Anticoagulants; Child; Enoxaparin; Humans; Infant; Parents; Quality of Life; Thrombosis

2022
Anti-Inflammatory Effects and Decreased Formation of Neutrophil Extracellular Traps by Enoxaparin in COVID-19 Patients.
    International journal of molecular sciences, 2022, Apr-27, Volume: 23, Issue:9

    Topics: Anti-Inflammatory Agents; COVID-19 Drug Treatment; Cytokines; DNA; Enoxaparin; Extracellular Traps;

2022
The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells.
    BMC musculoskeletal disorders, 2022, May-30, Volume: 23, Issue:1

    Topics: Animals; Bone Cements; CD40 Antigens; Endothelial Cells; Enoxaparin; Humans; Materials Testing; Poly

2022
An Open-Label, Single-Arm, Pilot Intervention Study to Assess the Efficacy and Safety of Apixaban in Heparin-Induced Thrombocytopenia.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:11

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Pilot Projects; Pyraz

2022
Prophylactic Enoxaparin Against Catheter-Associated Thrombosis in Postoperative Cardiac Children: An Interrupted Time Series Analysis.
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2022, 10-01, Volume: 23, Issue:10

    Topics: Anticoagulants; Central Venous Catheters; Child; Enoxaparin; Humans; Infant; Interrupted Time Series

2022
Enoxaparin to Prevent Catheter-Associated Thrombosis: Effective, But Is This a Tool We Need?
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2022, 10-01, Volume: 23, Issue:10

    Topics: Anticoagulants; Catheters; Enoxaparin; Humans; Thrombosis

2022
Assessment of BMI and Venous Thromboembolism Rates in Patients on Standard Chemoprophylaxis Regimens After Undergoing Free Tissue Transfer to the Head and Neck.
    JAMA otolaryngology-- head & neck surgery, 2022, 11-01, Volume: 148, Issue:11

    Topics: Anticoagulants; Body Mass Index; Chemoprevention; Cohort Studies; Enoxaparin; Female; Humans; Male;

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
    Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6

    Topics: Aged; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Hemorrhage; Humans; Male; SARS-

2022
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
    Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:1

    Topics: Anticoagulants; Catheters; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans;

2023
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report.
    Journal of cardiothoracic surgery, 2023, Apr-11, Volume: 18, Issue:1

    Topics: Anticoagulants; Enoxaparin; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Heparin, Low-M

2023
Comparison of edoxaban and enoxaparin in a rat model of AlCl
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:12

    Topics: Animals; Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Male; Rats; Rats, Wistar; Superior Sagit

2023
Practice patterns in the management of pediatric iliofemoral arterial thrombosis.
    Surgery, 2023, Volume: 174, Issue:4

    Topics: Adult; Blood Coagulation; Child; Enoxaparin; Heparin; Humans; Infant; Retrospective Studies; Thrombo

2023
Thromboprophylaxis in pediatric patients with earthquake-related crush syndrome: a single centre experience.
    Pediatric surgery international, 2023, Aug-16, Volume: 39, Issue:1

    Topics: Adolescent; Anticoagulants; Child; Crush Syndrome; Earthquakes; Enoxaparin; Female; Humans; Male; Th

2023
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.
    JAMA oncology, 2023, Nov-01, Volume: 9, Issue:11

    Topics: Adult; Aged; Anticoagulants; Biomarkers; Enoxaparin; Gastrointestinal Neoplasms; Hemorrhage; Humans;

2023
Transesophageal echocardiography-guided closure of electrically isolated left atrial appendage to constrain a rapidly growing thrombus despite anticoagulation and sinus rhythm.
    Journal of cardiovascular electrophysiology, 2020, Volume: 31, Issue:1

    Topics: Action Potentials; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial

2020
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
    The American journal of medicine, 2020, Volume: 133, Issue:8

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bi

2020
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial.
    European journal of clinical investigation, 2020, Volume: 50, Issue:5

    Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of T

2020
Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report.
    BMC cardiovascular disorders, 2020, 04-19, Volume: 20, Issue:1

    Topics: Adult; Anterior Wall Myocardial Infarction; Anticoagulants; Contraceptives, Oral, Combined; Contrace

2020
Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.
    Journal of thrombosis and thrombolysis, 2020, Volume: 50, Issue:1

    Topics: Anticoagulants; Biomarkers, Pharmacological; Blood Coagulation; Body Weight; Drug Dosage Calculation

2020
Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.
    Blood transfusion = Trasfusione del sangue, 2020, Volume: 18, Issue:3

    Topics: Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; Hemostasis; Humans; I

2020
Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia.
    The American journal of case reports, 2020, May-29, Volume: 21

    Topics: Aged; Antithrombins; Arginine; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pipecolic Acids; Py

2020
How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report.
    Journal of thrombosis and thrombolysis, 2020, Volume: 50, Issue:4

    Topics: Aged; Betacoronavirus; Blood Coagulation; Coronavirus Infections; COVID-19; Enoxaparin; Female; Fibr

2020
Priapism in a patient with coronavirus disease 2019 (COVID-19).
    The American journal of emergency medicine, 2021, Volume: 39

    Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Male; Middle Aged; Priapism; Thrombosis

2021
Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset.
    Echocardiography (Mount Kisco, N.Y.), 2020, Volume: 37, Issue:8

    Topics: Aged; Anticoagulants; Computed Tomography Angiography; COVID-19; Dyspnea; Echocardiography; Enoxapar

2020
COVID-19 associated with extensive pulmonary arterial, intracardiac and peripheral arterial thrombosis.
    BMJ case reports, 2020, Aug-03, Volume: 13, Issue:8

    Topics: Anticoagulants; Betacoronavirus; Clinical Deterioration; Computed Tomography Angiography; Coronaviru

2020
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
    Journal of thrombosis and thrombolysis, 2021, Volume: 51, Issue:2

    Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Follow-Up Studies; H

2021
Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction.
    Circulation journal : official journal of the Japanese Circulation Society, 2020, 09-25, Volume: 84, Issue:10

    Topics: Aged; Anterior Wall Myocardial Infarction; Anticoagulants; Dual Anti-Platelet Therapy; Echocardiogra

2020
Rotational thromboelastometry in young, previously healthy patients with SARS-Cov2.
    Journal of clinical anesthesia, 2020, Volume: 67

    Topics: Adult; Anticoagulants; Blood Coagulation Disorders; COVID-19; Enoxaparin; Heparin; Humans; Pyrazoles

2020
Inferior mesenteric vein thrombosis and COVID-19.
    Revista da Sociedade Brasileira de Medicina Tropical, 2020, Volume: 53

    Topics: Adult; Analgesics; Anticoagulants; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; E

2020
The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
    Thrombosis research, 2020, Volume: 196

    Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Factor Xa In

2020
Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study.
    Minerva medica, 2020, Volume: 111, Issue:4

    Topics: Aged; Anticoagulants; Body Mass Index; Case-Control Studies; COVID-19; Enoxaparin; Female; Heparin,

2020
Thromboprophylaxis in congenital nephrotic syndrome: 15-year experience from a national cohort.
    Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:5

    Topics: Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Nephrotic Syndrome; Thrombosis; Venous Thromb

2021
Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).
    Seminars in thrombosis and hemostasis, 2021, Volume: 47, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Body Weight; C-Reactive Protein; COVID-19; Dose-Response Re

2021
Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Journal of pediatric hematology/oncology, 2021, Oct-01, Volume: 43, Issue:7

    Topics: Anticoagulants; Child, Preschool; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Follow-Up Stu

2021
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.
    The American journal of gastroenterology, 2021, 07-01, Volume: 116, Issue:7

    Topics: Adult; Aged; Algorithms; Anticoagulants; Combined Modality Therapy; Enoxaparin; Female; Hemorrhage;

2021
Enoxaparin Use and Adverse Events in Outpatients With a Continuous Flow Left Ventricular Assist Device at a Single Institution.
    Journal of pharmacy practice, 2022, Volume: 35, Issue:3

    Topics: Adolescent; Anticoagulants; Enoxaparin; Heart-Assist Devices; Hemorrhage; Humans; Outpatients; Prosp

2022
Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry.
    Journal of medical virology, 2021, Volume: 93, Issue:7

    Topics: Anticoagulants; Blood Coagulation; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Healthcare

2021
Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.
    Clinical drug investigation, 2021, Volume: 41, Issue:8

    Topics: Anticoagulants; Aspirin; COVID-19; Enoxaparin; Humans; Respiration, Artificial; Retrospective Studie

2021
COVID-19 and Hepatic Artery Thrombosis: A Case Report.
    The American journal of case reports, 2021, Aug-01, Volume: 22

    Topics: COVID-19; Enoxaparin; Female; Hepatic Artery; Humans; Middle Aged; SARS-CoV-2; Thrombosis

2021
Anticoagulation prescribing patterns in patients with cancer.
    Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1

    Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle

2018
Treatment of Prosthetic Valve Thrombosis with Bolus Dose Tenecteplase: An Experience from a Developing Country.
    The Journal of heart valve disease, 2017, Volume: 26, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aortic Valve; Developing Countries; Echocar

2017
Combined Treatment with an Anticoagulant and a Vasodilator Prevents Steroid-Associated Osteonecrosis of Rabbit Femoral Heads by Improving Hypercoagulability.
    BioMed research international, 2017, Volume: 2017

    Topics: Animals; Anticoagulants; Bone Morphogenetic Protein 2; Disease Models, Animal; Enoxaparin; Femur Hea

2017
Anticoagulant Bridge Comparison in Mechanical Circulatory Support Patients.
    ASAIO journal (American Society for Artificial Internal Organs : 1992), 2019, Volume: 65, Issue:1

    Topics: Anticoagulants; Enoxaparin; Female; Fondaparinux; Heart-Assist Devices; Humans; International Normal

2019
Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
    Cardiology in the young, 2018, Volume: 28, Issue:5

    Topics: Anticoagulants; Central Venous Catheters; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; F

2018
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Asp

2018
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2018, Volume: 53, Issue:5

    Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ

2018
Pulmonary saddle thrombus.
    QJM : monthly journal of the Association of Physicians, 2018, Dec-01, Volume: 111, Issue:12

    Topics: Computed Tomography Angiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Pulmona

2018
Women's views, adherence and experience with postnatal thromboprophylaxis.
    Thrombosis research, 2019, Volume: 173

    Topics: Adult; Anticoagulants; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Humans; Intermitte

2019
Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:6

    Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Antithrombin III Deficiency; Asparaginase; Chil

2019
Right heart masses in a patient with endometrial stromal sarcoma.
    Journal of clinical ultrasound : JCU, 2020, Volume: 48, Issue:2

    Topics: Echocardiography; Endometrial Neoplasms; Enoxaparin; Female; Fibrinolytic Agents; Heart Diseases; Hu

2020
Missed Heparin-Induced Thrombocytopenia (HIT) Diagnosis in a Patient with Acute Stent Thrombosis.
    The American journal of case reports, 2019, May-28, Volume: 20

    Topics: Aged; Anticoagulants; Coronary Artery Disease; Enoxaparin; Heparin; Humans; Male; Percutaneous Coron

2019
Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:6

    Topics: Adenosine; Animals; Anticoagulants; Chlorides; Contrast Media; Enoxaparin; Ferric Compounds; Male; M

2013
Spinal haematoma after removal of a thoracic epidural catheter in a patient with coagulopathy resulting from unexpected vitamin K deficiency.
    Anaesthesia, 2013, Volume: 68, Issue:8

    Topics: Aged; Analgesia, Epidural; Anesthesia, General; Anticoagulants; Blood Coagulation Disorders; Blood C

2013
Anticoagulation in cirrhosis: ready … set … wait!
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:3

    Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re

2013
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases;

2013
How I treat heterozygous hereditary antithrombin deficiency in pregnancy.
    Thrombosis and haemostasis, 2013, Volume: 110, Issue:3

    Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Drug Administration Schedule; Enoxaparin; Fema

2013
Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI.
    Herz, 2014, Volume: 39, Issue:7

    Topics: Anticoagulants; Enoxaparin; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Thro

2014
Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
    International journal of obstetric anesthesia, 2013, Volume: 22, Issue:4

    Topics: Adult; Anticoagulants; Body Mass Index; Cesarean Section; Cohort Studies; Enoxaparin; Factor Xa Inhi

2013
Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:6

    Topics: Age Factors; Anticoagulants; Antithrombin III; Critical Illness; Dose-Response Relationship, Drug; D

2014
Pulmonary embolism as a first manifestation of intracardiac extension of an endometrial stromal sarcoma.
    Archivos de bronconeumologia, 2014, Volume: 50, Issue:11

    Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endometrial Neoplasms; E

2014
Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:4

    Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re

2014
A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator.
    Cardiology in the young, 2015, Volume: 25, Issue:4

    Topics: Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Vessel Anomalies; Coronary V

2015
Anticoagulation management of left ventricular assist devices.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Heart Failure; Heart Transplantation; Heart Ventricles;

2015
Structural and functional analyses of biosimilar enoxaparins available in Brazil.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:1

    Topics: Animals; Anticoagulants; Biosimilar Pharmaceuticals; Blood Coagulation; Blood Coagulation Tests; Bra

2015
Pregnancy in a patient with hepatic artery thrombosis after liver transplantation: a case report.
    Transplantation proceedings, 2014, Volume: 46, Issue:8

    Topics: Activated Protein C Resistance; Adult; Anticoagulants; Collateral Circulation; Enoxaparin; Female; H

2014
The balance of pro- and anticoagulant processes underlying thrombin generation.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:3

    Topics: alpha-Macroglobulins; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Computational Biolo

2015
Thrombosis of a mechanical tricuspid valve prosthesis resolved with fibrinolysis.
    Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:12

    Topics: Drug Therapy, Combination; Echocardiography, Three-Dimensional; Enoxaparin; Female; Fibrinolytic Age

2014
Partial segmental thrombosis of the corpus cavernosum (PSTCC) diagnosed by contrast-enhanced ultrasound: a case report.
    BMC urology, 2014, Dec-17, Volume: 14

    Topics: Adult; Anticoagulants; Aspirin; Contrast Media; Edema; Enoxaparin; Humans; Male; Pain; Penile Diseas

2014
Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:2

    Topics: Anticoagulants; Antithrombin III; Enoxaparin; Factor Xa; Freezing; Hemolysis; Humans; Male; Thrombos

2015
National survey on thromboprophylaxis and anticoagulant or antiplatelet management in neurosurgical and neurocritical patients.
    Revista espanola de anestesiologia y reanimacion, 2015, Volume: 62, Issue:10

    Topics: Anesthesiology; Anticoagulants; Critical Care; Enoxaparin; Health Care Surveys; Humans; Intermittent

2015
Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
    BMJ case reports, 2015, Apr-09, Volume: 2015

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Hematuria; Hemorrhage; Humans;

2015
Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.
    Journal of perinatology : official journal of the California Perinatal Association, 2015, Volume: 35, Issue:10

    Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Infant, Newborn; Male;

2015
Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2016, Volume: 27, Issue:2

    Topics: Adult; Anticoagulants; Blood Platelets; Dabigatran; Disseminated Intravascular Coagulation; Enoxapar

2016
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
    Thrombosis research, 2015, Volume: 136, Issue:6

    Topics: Anticoagulants; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Enoxaparin; Factor Xa; Female;

2015
Modulation of Thrombosis Significantly Reduces Testicular Damage after Testicular Torsion in Rats: Anti-Thrombotic Treatment and Testicular Torsion.
    Urology, 2016, Volume: 88

    Topics: Animals; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Male; Random Allocation; Rats; Rats, Wista

2016
[Bullous haemorrhagic dermatosis at distant sites due to enoxaparin: An uncommon secondary effect in an anticoagulated oncology patient].
    Semergen, 2016, Volume: 42, Issue:7

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Enoxaparin; Female; Humans; Skin Diseases, Vesiculobull

2016
Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:4

    Topics: Allosteric Site; Animals; Anticoagulants; Binding Sites; Bleeding Time; Blood Coagulation; Blood Coa

2016
In the nick of time: arterial thrombosis on starting combination chemotherapy in metastatic gastric adenocarcinoma.
    BMJ case reports, 2016, Feb-25, Volume: 2016

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Enoxaparin; Humans; Male; Pall

2016
[Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis].
    Khirurgiia, 2016, Issue:2

    Topics: Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Female; Humans; International Normalized Ratio; L

2016
Free-floating thrombus in a stenotic supraclinoid left internal carotid artery.
    BMJ case reports, 2016, Mar-30, Volume: 2016

    Topics: Aged; Anticoagulants; Aphasia; Carotid Artery, Internal; Carotid Stenosis; Enoxaparin; Female; Human

2016
Partial thrombosis of the corpus cavernosum: should we dig deeper into coagulopathy disorders?
    Andrologia, 2016, Volume: 48, Issue:10

    Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; Humans; Magnetic Resonance

2016
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
    Artificial organs, 2017, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Extracorporeal Membrane Oxyg

2017
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
    Khirurgiia, 2016, Issue:5

    Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation

2016
Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
    Translational research : the journal of laboratory and clinical medicine, 2016, Volume: 177

    Topics: Adult; Animals; Anticoagulants; Bleeding Time; Cell Survival; Enoxaparin; Fondaparinux; Heparin; Hum

2016
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
    Thrombosis research, 2017, Volume: 150

    Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhos

2017
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
    Thrombosis research, 2016, Volume: 148

    Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombo

2016
Images in cardiovascular medicine. Regression of thrombus and electrocardiographic changes with thrombolytic therapy in acute massive pulmonary embolism.
    Circulation, 2008, Nov-18, Volume: 118, Issue:21

    Topics: Coronary Angiography; Creatine Kinase; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans;

2008
Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation.
    Journal of cardiovascular electrophysiology, 2009, Volume: 20, Issue:4

    Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Catheter A

2009
Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:1

    Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Dosage Calculations; Dru

2009
[Leg venous thrombosis after work accident: serious surprise in echocardiography].
    MMW Fortschritte der Medizin, 2008, Nov-20, Volume: 150, Issue:47

    Topics: Accidents, Occupational; Adult; Casts, Surgical; Critical Care; Echocardiography, Doppler, Color; En

2008
Clinical management of thrombosis in inherited factor VII deficiency: a description of two cases.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:2

    Topics: Acenocoumarol; Aged; Aged, 80 and over; Anticoagulants; Drug Monitoring; Enoxaparin; Factor VII Defi

2009
Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis.
    Pediatric blood & cancer, 2009, Volume: 53, Issue:1

    Topics: Anticoagulants; Compartment Syndromes; Enoxaparin; Humans; Infant; Infant, Newborn; Male; Ornithine

2009
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5

    Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr

2009
Aortic thrombosis in infancy.
    Tennessee medicine : journal of the Tennessee Medical Association, 2009, Volume: 102, Issue:4

    Topics: Anticoagulants; Aortic Diseases; Aspirin; Echocardiography, Doppler; Enoxaparin; Female; Humans; Inf

2009
Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:7

    Topics: Animals; Anticoagulants; Chromatography, Affinity; Chromatography, Gel; Dogs; Enoxaparin; Factor Xa

2009
Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.
    Journal of neuro-oncology, 2009, Volume: 93, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Chemotherapy, Adjuvant; Enoxaparin; Female; Humans;

2009
Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention.
    Texas Heart Institute journal, 2009, Volume: 36, Issue:2

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Biomarkers; Enoxaparin; Eptifi

2009
In vitro effects of detergent sclerosants on antithrombotic mechanisms.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2009, Volume: 38, Issue:2

    Topics: Anticoagulants; Antithrombins; Blood Coagulation; Detergents; Dose-Response Relationship, Drug; Enox

2009
Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach.
    Journal of thrombosis and thrombolysis, 2010, Volume: 29, Issue:3

    Topics: Cardiac Catheterization; Dalteparin; Enoxaparin; Heart Diseases; Heparin, Low-Molecular-Weight; Huma

2010
Paraprosthetic leak unmasked by combined enoxaparin/warfarin therapy for thrombosed mitral valve.
    Echocardiography (Mount Kisco, N.Y.), 2009, Volume: 26, Issue:9

    Topics: Anticoagulants; Drug Therapy, Combination; Echocardiography, Transesophageal; Enoxaparin; Fibrinolyt

2009
Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:3

    Topics: Antibodies; Anticoagulants; Body Mass Index; Drug Administration Schedule; Enoxaparin; Evidence-Base

2010
Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients.
    International urology and nephrology, 2011, Volume: 43, Issue:2

    Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Constriction, Pathologic; Enoxaparin; Female; Humans;

2011
Prevalence and clinical characteristics associated with left atrial appendage thrombus in fully anticoagulated patients undergoing catheter-directed atrial fibrillation ablation.
    Journal of cardiovascular electrophysiology, 2010, Aug-01, Volume: 21, Issue:8

    Topics: Adult; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Chi-Square Di

2010
The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:4

    Topics: Anticoagulants; Antithrombin III; Arginine; Blood Coagulation; Blood Platelets; Cardiac Catheterizat

2010
Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Cardiology in the young, 2010, Volume: 20, Issue:2

    Topics: Anticoagulants; Creatinine; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; H

2010
Thrombocytosis associated with enoxaparin: A very rare cause in newborns.
    Platelets, 2010, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Newborn, Dis

2010
Fondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.
    Vascular health and risk management, 2010, Apr-15, Volume: 6

    Topics: Acute Coronary Syndrome; Anticoagulants; Catheterization; Enoxaparin; Fondaparinux; Hirudins; Humans

2010
Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer.
    International journal of hematology, 2010, Volume: 91, Issue:5

    Topics: Anticoagulants; Antineoplastic Agents; Aorta; Cisplatin; Enoxaparin; Humans; Lung Neoplasms; Male; M

2010
Renal function and thromboprophylaxis in critically ill patients.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Anticoagulants; Critical Illness; Enoxaparin; Humans; Kidney; Kidney Function Tests; Thrombosis

2010
Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2011, Volume: 17, Issue:5

    Topics: Adult; Echocardiography, Transesophageal; Enoxaparin; Female; Fibrinolytic Agents; Heart Valve Prost

2011
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Blood, 2010, Nov-25, Volume: 116, Issue:22

    Topics: Animals; Anticoagulants; Clopidogrel; Drug Combinations; Enoxaparin; Factor XI; Hemorrhage; Male; Mi

2010
Error in body weight estimation leads to inadequate parenteral anticoagulation.
    The American journal of emergency medicine, 2011, Volume: 29, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Chi-Square Distribution; Em

2011
[Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].
    Herz, 2010, Volume: 35, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Atrial Fibrillation; Drug T

2010
Acute myocardial infarction and renal infarction in a bodybuilder using anabolic steroids.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:4

    Topics: Adult; Anabolic Agents; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopid

2010
Rate of wound complications with enoxaparin use among women at high risk for postpartum thrombosis.
    Obstetrics and gynecology, 2011, Volume: 117, Issue:1

    Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Puerperal Disorders; Retrospect

2011
Do sick preterm babies need adult levels of AntiXa units for thrombolysis?
    Thrombosis research, 2011, Volume: 127, Issue:5

    Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Agents; Humans; Infant, Newborn; I

2011
Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:2

    Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous;

2011
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
    The Journal of thoracic and cardiovascular surgery, 2011, Volume: 141, Issue:6

    Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Co

2011
Effort thrombosis in a young triathlete: an unusual presentation of painless neck swelling secondary to right brachiocephalic vein thrombosis.
    Singapore medical journal, 2011, Volume: 52, Issue:3

    Topics: Adult; Anticoagulants; Arm; Athletes; Brachiocephalic Veins; Enoxaparin; Humans; Male; Thrombosis; T

2011
Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin.
    Klinische Padiatrie, 2011, Volume: 223, Issue:3

    Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Antithrombins;

2011
Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2011, Volume: 158, Issue:1

    Topics: Adult; Anticoagulants; Body Weight; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Comp

2011
Generic versions of enoxaparin available for clinical use in Brazil are similar to the original drug.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:7

    Topics: Animals; Anticoagulants; Brazil; Drugs, Generic; Enoxaparin; Hemorrhage; Magnetic Resonance Spectros

2011
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
    Cardiovascular research, 2011, Oct-01, Volume: 92, Issue:1

    Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary

2011
Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
    Pharmaceutical research, 2012, Volume: 29, Issue:1

    Topics: Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Drug Monitoring; Enoxaparin;

2012
Thrombosis-induced ulcerations of the lower legs with coexistent anetoderma due to anti-thrombin III deficiency.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:4

    Topics: Anetoderma; Antithrombin III Deficiency; Enoxaparin; Humans; Leg Ulcer; Thrombosis

2011
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo.
    Blood, 2011, Dec-15, Volume: 118, Issue:25

    Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Catheters; Dis

2011
Dabigatran after cardiac surgery: caution advised.
    The Journal of thoracic and cardiovascular surgery, 2011, Volume: 142, Issue:5

    Topics: Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Enoxaparin; Fibrinolytic Agent

2011
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
    European journal of pharmacology, 2011, Dec-30, Volume: 673, Issue:1-3

    Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Bleeding Time; Disease Models,

2011
Dabigatran etexilate in mechanical valve thromboprophylaxis.
    The Journal of thoracic and cardiovascular surgery, 2011, Volume: 142, Issue:6

    Topics: Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Enoxaparin; Fibrinolytic Agent

2011
Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
    Acta paediatrica (Oslo, Norway : 1992), 2012, Volume: 101, Issue:4

    Topics: Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fema

2012
Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:2

    Topics: Animals; Anticoagulants; Blood Coagulation; Brazil; Disease Models, Animal; Drugs, Generic; Enoxapar

2012
Intrauterine upper extremity thrombosis successfully treated with recombinant tissue plasminogen activator, enoxaparin and collagenase.
    Acta haematologica, 2012, Volume: 127, Issue:3

    Topics: Collagenases; Enoxaparin; Fetal Diseases; Fibrinolytic Agents; Humans; Infant, Newborn; Male; Necros

2012
A giant tumor thrombi filling right ventricle in a thrombocytopenic patient with renal cell carcinoma.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2012, Apr-20, Volume: 12, Issue:3

    Topics: Anticoagulants; Carcinoma, Renal Cell; Chest Pain; Dyspnea; Echocardiography; Enoxaparin; Heart Vent

2012
Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation.
    The Journal of pediatrics, 2012, Volume: 161, Issue:3

    Topics: Anticoagulants; Cross-Sectional Studies; Enoxaparin; Female; Fontan Procedure; Heart Defects, Congen

2012
LMWH - action-monitoring for all patients.
    Acta paediatrica (Oslo, Norway : 1992), 2012, Volume: 101, Issue:8

    Topics: Enoxaparin; Factor Xa; Female; Fibrinolytic Agents; Humans; Infant, Premature, Diseases; Male; Throm

2012
Extensive skin necrosis induced by low-molecular-weight heparin in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012, Volume: 18, Issue:4

    Topics: Antiphospholipid Syndrome; Aspirin; Drug Eruptions; Drug Therapy, Combination; Enoxaparin; Female; F

2012
Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Adm

2012
[Early asymptomatic pacemaker lead thrombosis successfully treated with pharmacotherapy].
    Kardiologia polska, 2012, Volume: 70, Issue:6

    Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Equipment Failure; Female; Humans; Pacemaker, Artific

2012
Successful use of low molecular weight heparin in intracardiac thrombus of an extremely low birth weight infant.
    Indian journal of pediatrics, 2013, Volume: 80, Issue:9

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography; Enoxaparin; Female

2013
Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression.
    Fertility and sterility, 2012, Volume: 98, Issue:4

    Topics: Abortion, Habitual; Anticoagulants; Cell Differentiation; Cell Movement; Cells, Cultured; Cysteine-R

2012
Severe hyperkalemia in critically ill patients treated with prophylactic doses of enoxaparin.
    Intensive care medicine, 2012, Volume: 38, Issue:11

    Topics: Aged; Enoxaparin; Female; Fibrinolytic Agents; Humans; Hyperkalemia; Intensive Care Units; Male; Mid

2012
[Comparative analysis of arterial bioprostheses with various antithrombotic modification].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2012, Volume: 18, Issue:2

    Topics: Biological Availability; Bioprosthesis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantatio

2012
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facili

2013
Prophylactic anticoagulation in cirrhotics: a paradox for prime time?
    Gastroenterology, 2012, Volume: 143, Issue:5

    Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re

2012
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:1

    Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em

2013
Portal vein thrombosis in cirrhosis: ignore, prevent, or treat?
    Gastroenterology, 2013, Volume: 144, Issue:2

    Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re

2013
Reply: To PMID 22819864.
    Gastroenterology, 2013, Volume: 144, Issue:2

    Topics: Anticoagulants; DNA, Bacterial; Enoxaparin; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Re

2013
Ultra-low-molecular-weight heparins: precise structural features impacting specific anticoagulant activities.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:3

    Topics: Anticoagulants; Carbohydrate Sequence; Circular Dichroism; Enoxaparin; Glucosamine; Heparin; Heparin

2013
Low-molecular-weight heparin for vertebral artery dissection.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2002, Volume: 8, Issue:2

    Topics: Child; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Male; Thrombosis; Treatment Outcome; Verte

2002
[Prosthetic valve thrombosis].
    Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:15

    Topics: Anticoagulants; Aortic Valve; Enoxaparin; Fibrinolytic Agents; Heart Valve Diseases; Heart Valve Pro

2001
Regarding "Anticoagulation with enoxaparin versus intravenous unfractionated heparin in postoperative vascular surgery patients".
    Journal of vascular surgery, 2003, Volume: 37, Issue:3

    Topics: Anticoagulants; Enoxaparin; Heparin; Humans; Infusions, Intravenous; Injections, Subcutaneous; Posto

2003
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
    MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10

    Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin

2003
Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.
    Thrombosis and haemostasis, 2003, Volume: 90, Issue:2

    Topics: Animals; Anticoagulants; Blood Coagulation Tests; Enoxaparin; Fondaparinux; Heart Valve Prosthesis;

2003
Postoperative anticoagulation in vascular surgery--Part two: A summary of lessons learned in our successful discharge planning experience using enoxaparin after vascular surgery.
    Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2003, Volume: 21, Issue:4

    Topics: Anticoagulants; Drug Monitoring; Enoxaparin; Humans; Length of Stay; Nurse's Role; Patient Care Team

2003
Prosthetic heart valves and pregnancy.
    Circulation, 2003, Dec-09, Volume: 108, Issue:23

    Topics: Abnormalities, Drug-Induced; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Pre

2003
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:1

    Topics: Adolescent; Arteries; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infa

2004
Effect of multielement intravascular ultrasound on the anticoagulant potency of enoxaparin.
    The American journal of cardiology, 2004, Jun-01, Volume: 93, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Eptifibatide; Factor Xa; Female; Humans; Male; Middle Aged; Peptid

2004
An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
    Journal of pediatric hematology/oncology, 2004, Volume: 26, Issue:9

    Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Dose-Response Relationship, Drug; Enoxaparin; F

2004
Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:12

    Topics: Amidines; Animals; Anticoagulants; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Dos

2004
Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire international, 2005, Volume: 14, Issue:75

    Topics: Anticoagulants; Clinical Trials as Topic; Dalteparin; Drug Approval; Enoxaparin; France; Heparin, Lo

2005
Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.
    Farmaco (Societa chimica italiana : 1989), 2005, Volume: 60, Issue:3

    Topics: Anticoagulants; Chemistry, Pharmaceutical; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-W

2005
Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
    The Australasian journal of dermatology, 2005, Volume: 46, Issue:3

    Topics: Abdominal Wall; Adjuvants, Immunologic; Chondroitin Sulfates; Dermatan Sulfate; Enoxaparin; Female;

2005
The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:8

    Topics: Angina Pectoris; Anticoagulants; Blood Coagulation; Cardiac Catheterization; Coronary Angiography; D

2005
The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibito
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Anticoagulants; Coronary Disease; Drug Interactions; Endothelium, Vascular; Enoxaparin; Fibrinolytic

2005
Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Thrombosis research, 2006, Volume: 118, Issue:6

    Topics: Animals; Anticoagulants; Aspirin; Bleeding Time; Carotid Arteries; Clopidogrel; Dose-Response Relati

2006
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
    The Canadian journal of cardiology, 2006, May-01, Volume: 22, Issue:6

    Topics: Abciximab; Adult; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Ant

2006
Safer alternative to heparin identified.
    Health news (Waltham, Mass.), 2006, Volume: 12, Issue:7

    Topics: Anticoagulants; Enoxaparin; Fondaparinux; Humans; Leg; Polysaccharides; Thrombosis

2006
Risk of bleeding after elective percutaneous coronary intervention.
    The New England journal of medicine, 2006, Sep-07, Volume: 355, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Cause of Death; Enoxaparin; Hemorrhage; Heparin; Hum

2006
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
    Journal of thrombosis and thrombolysis, 2007, Volume: 23, Issue:3

    Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W

2007
Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis.
    Journal of thrombosis and thrombolysis, 2007, Volume: 23, Issue:2

    Topics: Adult; Anticoagulants; Enoxaparin; Factor VIII; Fibrinogen; Fibrinogens, Abnormal; Graft Survival; H

2007
Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival.
    Transplantation, 2006, Dec-27, Volume: 82, Issue:12

    Topics: Animals; Anticoagulants; Blood Coagulation; Enoxaparin; Graft Rejection; Graft Survival; Heart Trans

2006
[Analgesia for childbirth in a patient with factor V Leiden mutation].
    Revista espanola de anestesiologia y reanimacion, 2007, Volume: 54, Issue:1

    Topics: Activated Protein C Resistance; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants;

2007
Childhood-onset skin necrosis resulting from protein C deficiency.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:4

    Topics: Blood Component Transfusion; Child, Preschool; Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; H

2007
[The best of thrombosis in 2006].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100 Spec No 1

    Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Coronary Disease; Enoxaparin; Humans; Myocardi

2007
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:4

    Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Hum

2007
Macroscopic thrombus formation on angioplasty equipment following antithrombin therapy with enoxaparin.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Nov-15, Volume: 70, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment

2007
Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Pharmacotherapy, 2007, Volume: 27, Issue:9

    Topics: Anticoagulants; Bone Diseases, Metabolic; Catheters, Indwelling; Dose-Response Relationship, Drug; E

2007
Unbalanced protein S deficiency due to warfarin treatment as a possible cause for thrombosis.
    British journal of haematology, 2007, Volume: 139, Issue:2

    Topics: Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; International Normalized Ratio; Middl

2007
Catheter induced clot formation during angioplasty: an enoxaparin side effect?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Nov-15, Volume: 70, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Enoxaparin; Equipment Failur

2007
External iliac artery thrombosis after open reduction of an acetabular fracture: a case report.
    Journal of orthopaedic trauma, 2008, Volume: 22, Issue:1

    Topics: Acetabulum; Adult; Angiography; Anticoagulants; Enoxaparin; Female; Fracture Fixation, Internal; Fra

2008
Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome.
    Neurobiology of disease, 2008, Volume: 30, Issue:1

    Topics: Alprostadil; Analysis of Variance; Animals; Antiphospholipid Syndrome; Aspirin; Behavior, Animal; be

2008
[Stents, antiplatelet therapy, and surgery].
    Revista espanola de anestesiologia y reanimacion, 2008, Volume: 55, Issue:3

    Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female

2008
Cardioverter-defibrillator lead-related thrombus treated with prolonged anticoagulation in patient with prothrombotic disorder.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2008, Volume: 19, Issue:4

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Defibrillators, Implantable; Echocardiography; Eno

2008
In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus.
    Coronary artery disease, 2008, Volume: 19, Issue:4

    Topics: Cardiac Catheterization; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin; Humans; In Vitro Te

2008
Enoxaparin does not ameliorate limb ischemia-reperfusion injury.
    The Journal of surgical research, 2008, Jun-15, Volume: 147, Issue:2

    Topics: Animals; Anticoagulants; Biomarkers; Enoxaparin; Hindlimb; Inflammation; Male; Mice; Mice, Inbred C5

2008
Effect of dextran and enoxaparin on early ePTFE graft thrombogenicity in sheep.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 1995, Volume: 9, Issue:3

    Topics: Animals; Blood Vessel Prosthesis; Carotid Artery, Common; Dextrans; Double-Blind Method; Drug Therap

1995
Spinal subdural bleeding after attempted epidural and subsequent spinal anaesthesia in a patient on thromboprophylaxis with low molecular weight heparin.
    Acta anaesthesiologica Scandinavica, 1995, Volume: 39, Issue:4

    Topics: Aged; Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Female; Hematoma, Epidural, Cranial; Hem

1995
[Histologic changes in ligated stumps of ovarian blood vessels in preoperative low-molecular weight preventive heparin administration].
    Gynakologisch-geburtshilfliche Rundschau, 1995, Volume: 35, Issue:1

    Topics: Endothelium, Vascular; Enoxaparin; Female; Humans; Hysterectomy; Injections, Subcutaneous; Ligation;

1995
Enoxaparin and a new look at clot prevention.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 1994, Volume: 3, Issue:1

    Topics: Enoxaparin; Humans; Thrombosis

1994
Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
    British journal of haematology, 1993, Volume: 84, Issue:2

    Topics: Adult; Dalteparin; Drug Eruptions; Enoxaparin; Erythema; Female; Femoral Vein; Humans; Iliac Vein; P

1993
Heparin-induced thrombocytopenia and paradoxical venous thromboses.
    Israel journal of medical sciences, 1993, Volume: 29, Issue:8

    Topics: Aged; Axillary Vein; Coronary Disease; Diabetes Mellitus, Type 2; Enoxaparin; Female; Femoral Vein;

1993
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
    Thrombosis and haemostasis, 1995, Volume: 74, Issue:2

    Topics: Animals; Anticoagulants; Aprotinin; Arthropod Proteins; Cattle; Cricetinae; Drug Evaluation, Preclin

1995
Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries.
    Microsurgery, 1995, Volume: 16, Issue:10

    Topics: Administration, Topical; Anastomosis, Surgical; Animals; Enoxaparin; Femoral Artery; Fibrinolytic Ag

1995
Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
    The Journal of pediatrics, 1996, Volume: 128, Issue:3

    Topics: Adolescent; Anticoagulants; Blood Coagulation Tests; Case-Control Studies; Catheters, Indwelling; Ch

1996
Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses.
    The Journal of hand surgery, 1997, Volume: 22, Issue:3

    Topics: Administration, Topical; Anastomosis, Surgical; Animals; Anticoagulants; Disease Models, Animal; Dos

1997
Low-molecular-weight heparin in the management of Trousseau's syndrome.
    Cancer, 1997, Aug-15, Volume: 80, Issue:4

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Synd

1997
Low-molecular-weight heparins.
    The New England journal of medicine, 1998, Mar-05, Volume: 338, Issue:10

    Topics: Anesthesia, Epidural; Anesthesia, Spinal; Enoxaparin; Hematoma; Humans; Spinal Diseases; Thrombosis

1998
Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery.
    Thrombosis research, 1998, Aug-01, Volume: 91, Issue:3

    Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Body Weight;

1998
Delayed-type hypersensitivity to subcutaneous enoxaparin.
    Allergy, 1998, Volume: 53, Issue:10

    Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Hypersensitivity, Delayed; Injections, Subcutaneou

1998
Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons.
    The Journal of thoracic and cardiovascular surgery, 1998, Volume: 116, Issue:6

    Topics: Animals; Anticoagulants; Bleeding Time; Cardiopulmonary Bypass; Complement Activation; Enoxaparin; F

1998
Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin.
    Acta haematologica, 1999, Volume: 101, Issue:1

    Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Complications, He

1999
Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin.
    British journal of obstetrics and gynaecology, 1999, Volume: 106, Issue:6

    Topics: Enoxaparin; Factor Xa Inhibitors; Heparin; Humans; Thrombolytic Therapy; Thrombosis

1999
Treatment of mobile left ventricular thrombus with low-molecular-weight heparin.
    The New England journal of medicine, 1999, Sep-30, Volume: 341, Issue:14

    Topics: Enoxaparin; Fibrinolytic Agents; Heart Diseases; Heart Ventricles; Humans; Male; Middle Aged; Thromb

1999
Better control coming for clotting and bleeding.
    JAMA, 1999, Oct-27, Volume: 282, Issue:16

    Topics: Anticoagulants; Blood Coagulation Factors; Enoxaparin; Genetic Therapy; Hemophilia A; Hemostasis; Hu

1999
Low-molecular-weight heparin for prosthetic heart valves: treatment failure.
    The Annals of thoracic surgery, 2000, Volume: 69, Issue:1

    Topics: Adult; Aged; Anticoagulants; Aortic Valve; Contraindications; Echocardiography; Enoxaparin; Female;

2000
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
    BJOG : an international journal of obstetrics and gynaecology, 2000, Volume: 107, Issue:3

    Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V;

2000
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    European journal of pharmacology, 2000, Apr-21, Volume: 395, Issue:1

    Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Antithrombins; Arteriovenous Shunt, Surgic

2000
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
    Thrombosis and haemostasis, 2000, Volume: 83, Issue:5

    Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants;

2000
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
    Thrombosis and haemostasis, 2000, Volume: 84, Issue:1

    Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H

2000
Thromboprophylaxis using a low molecular weight heparin delays fracture repair.
    Clinical orthopaedics and related research, 2000, Issue:381

    Topics: Animals; Anticoagulants; Biomechanical Phenomena; Bone and Bones; Bony Callus; Disease Models, Anima

2000
A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report.
    The Journal of heart valve disease, 2000, Volume: 9, Issue:6

    Topics: Adult; Anticoagulants; Dilatation and Curettage; Enoxaparin; Female; Heart Valve Prosthesis; Heart V

2000
Use of enoxaparin in a preterm infant.
    The Annals of pharmacotherapy, 2000, Volume: 34, Issue:12

    Topics: Anticoagulants; Enoxaparin; Humans; Infant, Newborn; Infant, Premature, Diseases; Thrombosis

2000
Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
    American journal of hematology, 2001, Volume: 67, Issue:1

    Topics: Adult; Anticoagulants; Creatine; Drug Monitoring; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molec

2001
Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica.
    Spine, 2001, Apr-15, Volume: 26, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Anticoagulants; Antirheumatic Agents; Cauda Equina; Edema; Enoxapar

2001
Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
    Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing, 2001, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Transfusion; Drug Monitoring; Enoxaparin; Fema

2001
Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis.
    BJOG : an international journal of obstetrics and gynaecology, 2001, Volume: 108, Issue:7

    Topics: Administration, Cutaneous; Adult; Anticoagulants; Aortic Valve; Contraindications; Enoxaparin; Femal

2001
Enoxaparin treatment in women with mechanical heart valves during pregnancy.
    American journal of obstetrics and gynecology, 2001, Volume: 185, Issue:3

    Topics: Adult; Antibodies; Anticoagulants; Aspirin; Enoxaparin; Factor Xa; Female; Heart Valve Diseases; Hea

2001
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
    European radiology, 2001, Volume: 11, Issue:12

    Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I

2001
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
    European journal of pharmacology, 2001, Dec-07, Volume: 432, Issue:2-3

    Topics: Amidines; Animals; Anticoagulants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; E

2001
[Heparin-induced thrombocytopenia in patients and prevention with low molecular weight heparin].
    Sbornik lekarsky, 2001, Volume: 102, Issue:3

    Topics: Abdomen; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male;

2001
Thromboprophylaxis with reviparin in a patient with acquired hemophilia.
    International journal of hematology, 2005, Volume: 81, Issue:2

    Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Carcinoma, Renal Cell; Factor VIII; Hemophilia

2005
Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury.
    Thrombosis research, 2000, Jun-15, Volume: 98, Issue:6

    Topics: Adenosine Diphosphate; Animals; Arteries; Blood Coagulation Tests; Blood Flow Velocity; Collagen; Di

2000
Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
    Thrombosis and haemostasis, 2001, Volume: 85, Issue:1

    Topics: Administration, Oral; Animals; Aorta; Blood Coagulation Tests; Dose-Response Relationship, Drug; End

2001
Low-molecular-weight heparin in patients with deep-vein thrombosis.
    The New England journal of medicine, 2001, Jul-26, Volume: 345, Issue:4

    Topics: Anticoagulants; Heparin; Heparin, Low-Molecular-Weight; Humans; Partial Thromboplastin Time; Seconda

2001
Low-molecular-weight heparin in patients with deep-vein thrombosis.
    The New England journal of medicine, 2001, Jul-26, Volume: 345, Issue:4

    Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Thrombosis

2001
[Facilitated patient management with low molecular weight heparin].
    MMW Fortschritte der Medizin, 2016, May-25, Volume: 158, Issue:10

    Topics: General Practice; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Thrombosis

2016
[Internist patients are strongly thrombosis endangered. CERTIFY study has arrived].
    MMW Fortschritte der Medizin, 2007, May-17, Volume: 149, Issue:20

    Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight;

2007
[LMWH and UFH in direct comparison. Consent: CERTIFY].
    MMW Fortschritte der Medizin, 2007, May-17, Volume: 149, Issue:20

    Topics: Age Factors; Aged; Anticoagulants; Antifibrinolytic Agents; Double-Blind Method; Follow-Up Studies;

2007
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients.
    Medicina (Kaunas, Lithuania), 2023, Feb-04, Volume: 59, Issue:2

    Topics: Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Portal Vein; Rec

2023
A Man with a Clot on his Platelets: Adrenal Carcinoma and Dynamic Right Ventricular Inflow Obstruction.
    The American journal of medicine, 2020, Volume: 133, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged, 80 and over; Anticoagulants; Dalteparin; H

2020
Word Thrombosis Day-5 years on.
    The Lancet. Haematology, 2019, Volume: 6, Issue:10

    Topics: Anniversaries and Special Events; Anticoagulants; Dalteparin; Global Burden of Disease; Humans; Risk

2019
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
    Critical care (London, England), 2020, 11-23, Volume: 24, Issue:1

    Topics: Aged; Anticoagulants; APACHE; COVID-19; Critical Illness; Dalteparin; Female; Humans; Intensive Care

2020
Analysis of blood clotting with the total thrombus analysis system in healthy dogs.
    Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 2021, Volume: 33, Issue:2

    Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dalteparin; Dogs; Fema

2021
Dalteparin in Newborn Thrombosis, Time for a New Starting Dose.
    Neonatology, 2021, Volume: 118, Issue:3

    Topics: Anticoagulants; Dalteparin; Humans; Infant; Infant, Newborn; Retrospective Studies; Thrombosis; Trea

2021
Dalteparin anticoagulation in paediatric home haemodialysis.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:12

    Topics: Adolescent; Age Factors; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Dalteparin; Dos

2018
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
    Journal of thrombosis and thrombolysis, 2019, Volume: 48, Issue:3

    Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Gastrointestinal Neoplasms; Humans; Markov Chains

2019
Arterial thrombosis after vehicular trauma and humeral fracture in a dog.
    Journal of the American Veterinary Medical Association, 2013, Aug-01, Volume: 243, Issue:3

    Topics: Accidents, Traffic; Animals; Anticoagulants; Clopidogrel; Dalteparin; Dog Diseases; Dogs; Female; Fo

2013
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.
    Intensive care medicine, 2013, Volume: 39, Issue:12

    Topics: Adult; Aged; Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Hospital Mor

2013
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Dalteparin; Female; Fibrinolytic Agents; Hospital

2014
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1

    Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog

2016
Dalteparin-sodium induced drug fever in a neonate.
    BMJ case reports, 2016, Oct-13, Volume: 2016

    Topics: Anticoagulants; Dalteparin; Fever; Heart Diseases; Humans; Infant, Newborn; Infant, Premature; Infan

2016
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2008, Volume: 19, Issue:6

    Topics: Adult; Antibody Specificity; Antigens, Human Platelet; Autoantibodies; Autoantigens; Dalteparin; Dos

2008
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
    Acta neurochirurgica, 2009, Volume: 151, Issue:10

    Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome;

2009
Administration of dalteparin based on the activated clotting time for prophylaxis of hepatic vessel thrombosis in living donor liver transplantation.
    Transplantation proceedings, 2009, Volume: 41, Issue:9

    Topics: Adult; Antithrombin III; Blood Coagulation; Blood Component Transfusion; Dalteparin; Female; Fibrino

2009
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep

2010
Anticoagulant-induced priapism progressing to penile gangrene: a devastating complication!
    BMJ case reports, 2012, Nov-21, Volume: 2012

    Topics: Adult; Anticoagulants; Brachial Artery; Dalteparin; Drug Therapy, Combination; Gangrene; Hemopneumot

2012
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
    Thrombosis research, 2002, Aug-15, Volume: 107, Issue:3-4

    Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response R

2002
Thrombophilic causes of retinal vascular thrombosis: etiology and treatment outcomes.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2002, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clinical Laboratory Techniques; Clopidogrel; Da

2002
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
    American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:2

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F

2003
Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury.
    Plastic and reconstructive surgery, 2003, Apr-15, Volume: 111, Issue:5

    Topics: Animals; Carotid Artery Thrombosis; Dalteparin; Dose-Response Relationship, Drug; Endarterectomy, Ca

2003
Cancer-associated thrombosis.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Anticoagulants; Dalteparin; Humans; Neoplasms; Pulmonary Embolism; Risk Factors; Secondary Preventio

2003
Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:5

    Topics: Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Cost-Benefit Analysis; Dalteparin; Economi

2003
Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Catheterization, Central Veno

2004
[Initial trials give hope. Anticoagulants against cancer?].
    MMW Fortschritte der Medizin, 2003, Apr-03, Volume: 145, Issue:14

    Topics: Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Fibrinolytic Agents; Heparin; Human

2003
Anticoagulation interruptus: not without risk.
    Circulation, 2004, Sep-21, Volume: 110, Issue:12

    Topics: Anticoagulants; Aspirin; Atrial Appendage; Atrial Fibrillation; Blood Loss, Surgical; Carotid Arteri

2004
[Paraneoplastic lupus anticoagulans syndrome].
    Zentralblatt fur Chirurgie, 2005, Volume: 130, Issue:4

    Topics: Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Studie

2005
Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits.
    Thrombosis and haemostasis, 1994, Volume: 71, Issue:3

    Topics: Animals; Dalteparin; Dextrans; Drug Synergism; Drug Therapy, Combination; Female; Fibrinolytic Agent

1994
Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1994, Volume: 5, Issue:2

    Topics: Animals; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Dalteparin; Dise

1994
Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1994, Volume: 5, Issue:2

    Topics: Adult; Blood Coagulation; Blood Donors; Cardiopulmonary Bypass; Dalteparin; Female; Hemostasis; Hepa

1994
Low molecular weight heparin (Fragmin) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits.
    European heart journal, 1994, Volume: 15, Issue:4

    Topics: Animals; Dalteparin; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination

1994
Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit.
    Artificial organs, 1993, Volume: 17, Issue:8

    Topics: Acute Kidney Injury; Adult; Aged; Blood Coagulation; Critical Care; Dalteparin; Female; Fibrinopepti

1993
Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits.
    Thrombosis research, 1995, Dec-01, Volume: 80, Issue:5

    Topics: Animals; Anticoagulants; Antithrombin III; Dalteparin; Disease Models, Animal; Disseminated Intravas

1995
Low molecular weight heparin ('fragmin') in haemodialysis: is laboratory monitoring worthwhile?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1995, Volume: 10, Issue:11

    Topics: Anticoagulants; Dalteparin; Female; Humans; Male; Middle Aged; Renal Dialysis; Thrombosis

1995
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Journal of cardiovascular pharmacology, 1996, Volume: 28, Issue:1

    Topics: Animals; Antithrombins; Arginine; Bleeding Time; Dalteparin; Dose-Response Relationship, Drug; Fibri

1996
Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Journal of internal medicine, 1996, Volume: 240, Issue:6

    Topics: Aged; Ambulatory Care; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Drug Administration Schedu

1996
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
    British journal of pharmacology, 1998, Volume: 123, Issue:1

    Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Bleeding Time; Blood Proteins; Dal

1998
Dalteparin for deep venous thrombosis: a hospital-in-the-home program.
    The Medical journal of Australia, 1998, Mar-16, Volume: 168, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dalteparin; Female; Hom

1998
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    The Journal of bone and joint surgery. American volume, 1998, Volume: 80, Issue:8

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul

1998
Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    The Journal of bone and joint surgery. American volume, 1998, Volume: 80, Issue:8

    Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Postoperative Complications; Pul

1998
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 292, Issue:1

    Topics: Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Blood Coagulation; Dalteparin; Dose-Response

2000
The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases.
    European journal of pediatrics, 1999, Volume: 158 Suppl 3

    Topics: Adolescent; Age Factors; Anticoagulants; Child; Child, Preschool; Dalteparin; Dose-Response Relation

1999
Activation of coagulation and fibrinolysis in microsurgical reconstructions in the lower extremities.
    British journal of plastic surgery, 2001, Volume: 54, Issue:7

    Topics: Adult; Aged; Analysis of Variance; Blood Coagulation; C-Reactive Protein; Dalteparin; Enzyme-Linked

2001
Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
    Viruses, 2022, 04-07, Volume: 14, Issue:4

    Topics: Aged; Anticoagulants; COVID-19 Drug Treatment; Female; Hospital Mortality; Humans; Male; Middle Aged

2022
Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study.
    Journal de medecine vasculaire, 2022, Volume: 47, Issue:2

    Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective Studies; Thrombosis; Tinzaparin; Venou

2022
Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study.
    Phlebology, 2021, Volume: 36, Issue:6

    Topics: Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Tinzaparin; Treat

2021
Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
    Thrombosis research, 2017, Volume: 157

    Topics: Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pr

2017
Evaluation of the age-dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:12

    Topics: Adolescent; Age Factors; Child; Child, Preschool; Cohort Studies; Drug Administration Schedule; Fact

2017
Case report: ischemic priapism secondary to tinzaparin.
    International journal of impotence research, 2018, Volume: 30, Issue:2

    Topics: Adult; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Priapism; Thrombosis; Tinza

2018
Mechanical Mitral Valve Thrombosis Secondary to Tinzaparin as an Anticoagulation Bridging Strategy.
    The Annals of thoracic surgery, 2018, Volume: 105, Issue:4

    Topics: Anticoagulants; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valv

2018
Utility of global hemostatic assays in the management of anticoagulation in a haemophilia patient.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2018, Volume: 24, Issue:4

    Topics: Anticoagulants; Coronary Angiography; Factor VIII; Hemophilia A; Hemorrhage; Humans; International N

2018
Tinzaparin safety and efficacy in pregnancy.
    Irish journal of medical science, 2014, Volume: 183, Issue:2

    Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag

2014
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
    BMJ case reports, 2013, Sep-17, Volume: 2013

    Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol

2013
Tinzaparin failure in a pregnant patient with a mitral metal valve.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2008, Volume: 28, Issue:5

    Topics: Adult; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; P

2008
Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, Volume: 21, Issue:1

    Topics: Adult; Anticoagulants; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Female; Heparin, Low-Mo

2010
Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days.
    Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:12

    Topics: Aged; Aged, 80 and over; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Lipoproteins; Male;

2003
Orally administered heparins prevent arterial thrombosis in a rat model.
    Thrombosis and haemostasis, 2004, Volume: 91, Issue:5

    Topics: Administration, Oral; Animals; Blood Flow Velocity; Carotid Artery Thrombosis; Disease Models, Anima

2004
Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
    Thrombosis and haemostasis, 2004, Volume: 92, Issue:4

    Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight

2004
The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis.
    Thrombosis research, 2006, Volume: 117, Issue:3

    Topics: Adult; Blood Coagulation; Factor Xa; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; F

2006
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1

    Topics: Animals; Anticoagulants; Cell Line, Tumor; Disaccharides; Factor Xa; Fibrinolytic Agents; Fondaparin

2005
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
    International angiology : a journal of the International Union of Angiology, 2006, Volume: 25, Issue:1

    Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen

2006
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
    Thrombosis and haemostasis, 2000, Volume: 84, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Factor Xa; Female; Fibrinolytic Agents; Hemorrhage; Heparin, L

2000